activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	2470108	CHEMBL1032251	Inhibition of AMPKalpha2 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL2116	Homo sapiens	INH	%	10.0
	2470108	CHEMBL1032251	Inhibition of AMPKalpha2 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL2116	Homo sapiens	INH	%	10.0
Not Evaluated	2476722	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582		Activity			CHEMBL2116	Homo sapiens	Activity		
Not Evaluated	2478561	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL2116	Homo sapiens	Activity		
	2478764	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755	=	Activity	%	25.75	CHEMBL2116	Homo sapiens	Activity	%	25.75
Not Evaluated	2479619	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312		Activity			CHEMBL2116	Homo sapiens	Activity		
	2479822	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Activity	%	25.4	CHEMBL2116	Homo sapiens	Activity	%	25.4
Active	2480619	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL2116	Homo sapiens	Activity		
	2480821	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Activity	%	4.0	CHEMBL2116	Homo sapiens	Activity	%	4.0
	2528953	CHEMBL985888	Inhibition of AMPK	B	O[C@H]1CC[C@H](c2n[nH]cc2-c2ccnc(NC3CCCC3)n2)CC1		CHEMBL507249	>	IC50	nM	30000.0	CHEMBL2116	Homo sapiens	IC50	uM	30.0
Not Evaluated	2577240	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL2116	Homo sapiens	Activity		
Not Evaluated	2577443	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL2116	Homo sapiens	Activity		
Not Evaluated	2593648	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097		Activity			CHEMBL2116	Homo sapiens	Activity		
	2593914	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519	=	Activity	%	14.35	CHEMBL2116	Homo sapiens	Activity	%	14.35
Not Evaluated	2594117	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL2116	Homo sapiens	Activity		
Not Evaluated	2594857	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL2116	Homo sapiens	Activity		
Not Evaluated	2595060	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL2116	Homo sapiens	Activity		
Not Evaluated	2596257	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342		Activity			CHEMBL2116	Homo sapiens	Activity		
Not Evaluated	2596460	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL2116	Homo sapiens	Activity		
Not Evaluated	2597729	CHEMBL982750	Binding affinity to human AMPKA2 at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL2116	Homo sapiens	Activity		
	2721549	CHEMBL1060957	Inhibition of AMPK at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	2897192	CHEMBL1063692	Percent residual AMPK activity in the presence of 10uM inhibitor	B	O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12		CHEMBL92361	=	Activity	%	92.0	CHEMBL2116	Homo sapiens	Activity	%	92.0
	2897193	CHEMBL1063692	Percent residual AMPK activity in the presence of 10uM inhibitor	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28	=	Activity	%	57.0	CHEMBL2116	Homo sapiens	Activity	%	57.0
	2897194	CHEMBL1063692	Percent residual AMPK activity in the presence of 10uM inhibitor	B	Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL289277	=	Activity	%	89.0	CHEMBL2116	Homo sapiens	Activity	%	89.0
	2897462	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897463	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897464	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897465	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897466	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897467	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897468	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	820.0	CHEMBL2116	Homo sapiens	Kd	nM	820.0
	2897469	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897470	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897471	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897472	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897473	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897474	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897475	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897476	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897477	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897478	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897479	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897480	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897481	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Kd	nM	1800.0	CHEMBL2116	Homo sapiens	Kd	nM	1800.0
	2897482	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897483	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897484	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897485	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897486	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897487	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	460.0	CHEMBL2116	Homo sapiens	Kd	nM	460.0
	2897488	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897489	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897490	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897491	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897492	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897493	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897494	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	12.0	CHEMBL2116	Homo sapiens	Kd	nM	12.0
	2897495	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	290.0	CHEMBL2116	Homo sapiens	Kd	nM	290.0
	2897496	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	89.0	CHEMBL2116	Homo sapiens	Kd	nM	89.0
	2897497	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	350.0	CHEMBL2116	Homo sapiens	Kd	nM	350.0
	2897498	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2897499	CHEMBL1060176	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	2921439	CHEMBL1059258	Inhibition of AMPKalpha2 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	96.0	CHEMBL2116	Homo sapiens	Activity	%	96.0
	2938531	CHEMBL1041334	Inhibition of AMPK at 2 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	5.0	CHEMBL2116	Homo sapiens	INH	%	5.0
	3331827	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3333242	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3334647	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3336067	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3337453	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3337701	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3339032	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3339288	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3340595	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3342011	CHEMBL1168786	Inhibition of AMPK-alpha2 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	3358454	CHEMBL1174068	Inhibition of AMPK-alpha2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	18.0	CHEMBL2116	Homo sapiens	INH	%	18.0
	3358896	CHEMBL1174068	Inhibition of AMPK-alpha2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	7.2	CHEMBL2116	Homo sapiens	INH	%	7.2
	3445028	CHEMBL1244724	Binding affinity to AMPK-alpha2	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	56.0	CHEMBL2116	Homo sapiens	Kd	nM	56.0
	3448880	CHEMBL1244724	Binding affinity to AMPK-alpha2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	460.0	CHEMBL2116	Homo sapiens	Kd	nM	460.0
	3449100	CHEMBL1244724	Binding affinity to AMPK-alpha2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	89.0	CHEMBL2116	Homo sapiens	Kd	nM	89.0
	3449560	CHEMBL1244724	Binding affinity to AMPK-alpha2	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	3449985	CHEMBL1244724	Binding affinity to AMPK-alpha2	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	3450914	CHEMBL1244724	Binding affinity to AMPK-alpha2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	3451204	CHEMBL1244724	Binding affinity to AMPK-alpha2	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	uM	10.0
	6340963	CHEMBL1827287	Activity of AMPK-alpha2 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	95.0	CHEMBL2116	Homo sapiens	Activity	%	95.0
	7567445	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7567933	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7568401	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7568833	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	290.0	CHEMBL2116	Homo sapiens	Kd	nM	290.0
	7569436	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7569908	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7570371	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	=	Kd	nM	770.0	CHEMBL2116	Homo sapiens	Kd	nM	770.0
	7570798	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	89.0	CHEMBL2116	Homo sapiens	Kd	nM	89.0
	7570952	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7571409	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7571885	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7572348	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7572764	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	49.0	CHEMBL2116	Homo sapiens	Kd	nM	49.0
	7572933	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7573390	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7573866	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	4.1	CHEMBL2116	Homo sapiens	Kd	nM	4.1
	7574335	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	460.0	CHEMBL2116	Homo sapiens	Kd	nM	460.0
	7574743	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7574911	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	84.0	CHEMBL2116	Homo sapiens	Kd	nM	84.0
	7575372	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7575843	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7576885	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7577344	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	1200.0	CHEMBL2116	Homo sapiens	Kd	nM	1200.0
	7577822	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	440.0	CHEMBL2116	Homo sapiens	Kd	nM	440.0
	7577850	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7578255	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	4700.0	CHEMBL2116	Homo sapiens	Kd	nM	4700.0
	7578893	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7579267	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7579717	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7580218	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7580621	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7581251	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7581636	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7582110	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7582574	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7582974	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	350.0	CHEMBL2116	Homo sapiens	Kd	nM	350.0
	7583597	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7583997	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7584468	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	=	Kd	nM	5000.0	CHEMBL2116	Homo sapiens	Kd	nM	5000.0
	7584930	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	750.0	CHEMBL2116	Homo sapiens	Kd	nM	750.0
	7585334	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7585893	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7586339	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7586810	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7587264	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7587446	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7587865	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7588318	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7588789	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7589240	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7589411	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7589835	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	56.0	CHEMBL2116	Homo sapiens	Kd	nM	56.0
	7590302	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7590776	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7591227	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7591384	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7591806	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	820.0	CHEMBL2116	Homo sapiens	Kd	nM	820.0
	7592278	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7592751	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7593351	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7593786	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7594258	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7594741	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7595319	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7595763	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7596266	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7596713	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7597291	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7597744	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7597775	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7598245	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL2116	Homo sapiens	Kd	nM	10000.0
	7598687	CHEMBL1908744	Binding constant for AMPK-alpha2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	12.0	CHEMBL2116	Homo sapiens	Kd	nM	12.0
Active	7970408	CHEMBL1930209	Activation of AMPK in human U937 cells assessed as increase in phosphorylated AMPK level at 1 to 10 uM after 1 hr by Western blot analysis	B	NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL1929247		Activity			CHEMBL2116	Homo sapiens	Activity		
	7970412	CHEMBL1930205	Inhibition of AMPK at 10 uM	B	NCCN1C(=O)S/C(=C\CCC2CCCCC2)C1=O		CHEMBL1929247	=	Inhibition	%	76.0	CHEMBL2116	Homo sapiens	INH	%	76.0
	7996674	CHEMBL1944005	Inhibition of AMPK-alpha2 at 1 uM	B	CNC(=O)c1cccc(F)c1Nc1nc(Nc2ccc3c(c2)NC(=O)[C@H](NC(=O)N2CCCC2)CC3(C)C)ncc1Cl		CHEMBL1939491	=	Inhibition	%	96.0	CHEMBL2116	Homo sapiens	INH	%	96.0
	8061253	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-2.35	CHEMBL2116	Homo sapiens	Inhibition	%	-2.35
	8061430	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-3.45	CHEMBL2116	Homo sapiens	Inhibition	%	-3.45
	8061761	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	2.34	CHEMBL2116	Homo sapiens	Inhibition	%	2.34
	8061952	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	4.46	CHEMBL2116	Homo sapiens	Inhibition	%	4.46
	8062176	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	8.64	CHEMBL2116	Homo sapiens	Inhibition	%	8.64
	8062292	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	0.94	CHEMBL2116	Homo sapiens	Inhibition	%	0.94
	8062678	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	3.9	CHEMBL2116	Homo sapiens	Inhibition	%	3.9
	8062776	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	4.28	CHEMBL2116	Homo sapiens	Inhibition	%	4.28
	8063000	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-1.56	CHEMBL2116	Homo sapiens	Inhibition	%	-1.56
	8063132	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	3.06	CHEMBL2116	Homo sapiens	Inhibition	%	3.06
	8063299	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.17	CHEMBL2116	Homo sapiens	Inhibition	%	0.17
	8063523	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	-8.45	CHEMBL2116	Homo sapiens	Inhibition	%	-8.45
	8063631	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.83	CHEMBL2116	Homo sapiens	Inhibition	%	0.83
	8064037	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.93	CHEMBL2116	Homo sapiens	Inhibition	%	0.93
	8064152	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	4.41	CHEMBL2116	Homo sapiens	Inhibition	%	4.41
	8064376	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	2.3	CHEMBL2116	Homo sapiens	Inhibition	%	2.3
	8064586	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	3.03	CHEMBL2116	Homo sapiens	Inhibition	%	3.03
	8064724	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-0.43	CHEMBL2116	Homo sapiens	Inhibition	%	-0.43
	8065114	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.53	CHEMBL2116	Homo sapiens	Inhibition	%	0.53
	8065230	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.23	CHEMBL2116	Homo sapiens	Inhibition	%	2.23
	8065454	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.56	CHEMBL2116	Homo sapiens	Inhibition	%	0.56
	8065629	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	4.13	CHEMBL2116	Homo sapiens	Inhibition	%	4.13
	8065968	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	10.09	CHEMBL2116	Homo sapiens	Inhibition	%	10.09
	8066178	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-1.43	CHEMBL2116	Homo sapiens	Inhibition	%	-1.43
	8066314	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	14.5	CHEMBL2116	Homo sapiens	Inhibition	%	14.5
	8066538	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	0.99	CHEMBL2116	Homo sapiens	Inhibition	%	0.99
	8066704	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	1.68	CHEMBL2116	Homo sapiens	Inhibition	%	1.68
	8067052	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	4.23	CHEMBL2116	Homo sapiens	Inhibition	%	4.23
	8067227	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	2.21	CHEMBL2116	Homo sapiens	Inhibition	%	2.21
	8067572	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	1.39	CHEMBL2116	Homo sapiens	Inhibition	%	1.39
	8067782	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	2.0	CHEMBL2116	Homo sapiens	Inhibition	%	2.0
	8068141	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	17.37	CHEMBL2116	Homo sapiens	Inhibition	%	17.37
	8068305	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	-0.83	CHEMBL2116	Homo sapiens	Inhibition	%	-0.83
	8068654	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.31	CHEMBL2116	Homo sapiens	Inhibition	%	0.31
	8068828	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	3.39	CHEMBL2116	Homo sapiens	Inhibition	%	3.39
	8069052	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	1.9	CHEMBL2116	Homo sapiens	Inhibition	%	1.9
	8069177	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	2.49	CHEMBL2116	Homo sapiens	Inhibition	%	2.49
	8069472	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	4.64	CHEMBL2116	Homo sapiens	Inhibition	%	4.64
	8069633	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.61	CHEMBL2116	Homo sapiens	Inhibition	%	1.61
	8069857	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	-0.13	CHEMBL2116	Homo sapiens	Inhibition	%	-0.13
	8069983	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	2.24	CHEMBL2116	Homo sapiens	Inhibition	%	2.24
	8070379	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	3.34	CHEMBL2116	Homo sapiens	Inhibition	%	3.34
	8070504	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.19	CHEMBL2116	Homo sapiens	Inhibition	%	0.19
	8070802	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	34.75	CHEMBL2116	Homo sapiens	Inhibition	%	34.75
	8071183	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.04	CHEMBL2116	Homo sapiens	Inhibition	%	1.04
	8071309	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.85	CHEMBL2116	Homo sapiens	Inhibition	%	0.85
	8071533	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	1.54	CHEMBL2116	Homo sapiens	Inhibition	%	1.54
	8071706	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	1.15	CHEMBL2116	Homo sapiens	Inhibition	%	1.15
	8071831	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	2.31	CHEMBL2116	Homo sapiens	Inhibition	%	2.31
	8072055	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	0.72	CHEMBL2116	Homo sapiens	Inhibition	%	0.72
	8072145	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	0.44	CHEMBL2116	Homo sapiens	Inhibition	%	0.44
	8072369	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	3.68	CHEMBL2116	Homo sapiens	Inhibition	%	3.68
	8072526	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.01	CHEMBL2116	Homo sapiens	Inhibition	%	0.01
	8072875	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.26	CHEMBL2116	Homo sapiens	Inhibition	%	-0.26
	8073042	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	5.5	CHEMBL2116	Homo sapiens	Inhibition	%	5.5
	8073391	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.67	CHEMBL2116	Homo sapiens	Inhibition	%	1.67
	8073510	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	0.59	CHEMBL2116	Homo sapiens	Inhibition	%	0.59
	8073734	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	12.28	CHEMBL2116	Homo sapiens	Inhibition	%	12.28
	8073967	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	2.04	CHEMBL2116	Homo sapiens	Inhibition	%	2.04
	8074119	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.9	CHEMBL2116	Homo sapiens	Inhibition	%	0.9
	8074473	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	1.18	CHEMBL2116	Homo sapiens	Inhibition	%	1.18
	8074630	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.24	CHEMBL2116	Homo sapiens	Inhibition	%	1.24
	8074981	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.57	CHEMBL2116	Homo sapiens	Inhibition	%	0.57
	8075316	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.28	CHEMBL2116	Homo sapiens	Inhibition	%	0.28
	8075553	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	6.62	CHEMBL2116	Homo sapiens	Inhibition	%	6.62
	8075694	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	-0.69	CHEMBL2116	Homo sapiens	Inhibition	%	-0.69
	8075918	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	-4.09	CHEMBL2116	Homo sapiens	Inhibition	%	-4.09
	8076060	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	0.8	CHEMBL2116	Homo sapiens	Inhibition	%	0.8
	8076208	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	2.59	CHEMBL2116	Homo sapiens	Inhibition	%	2.59
	8076432	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.45	CHEMBL2116	Homo sapiens	Inhibition	%	1.45
	8076566	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.77	CHEMBL2116	Homo sapiens	Inhibition	%	0.77
	8076892	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	2.58	CHEMBL2116	Homo sapiens	Inhibition	%	2.58
	8077139	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	24.57	CHEMBL2116	Homo sapiens	Inhibition	%	24.57
	8077491	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-0.06	CHEMBL2116	Homo sapiens	Inhibition	%	-0.06
	8077642	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	2.72	CHEMBL2116	Homo sapiens	Inhibition	%	2.72
	8078009	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.32	CHEMBL2116	Homo sapiens	Inhibition	%	1.32
	8078148	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	0.54	CHEMBL2116	Homo sapiens	Inhibition	%	0.54
	8078372	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	8.67	CHEMBL2116	Homo sapiens	Inhibition	%	8.67
	8078474	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-1.32	CHEMBL2116	Homo sapiens	Inhibition	%	-1.32
	8078724	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	68.09	CHEMBL2116	Homo sapiens	Inhibition	%	68.09
	8079064	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	2.95	CHEMBL2116	Homo sapiens	Inhibition	%	2.95
	8079222	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	0.26	CHEMBL2116	Homo sapiens	Inhibition	%	0.26
	8079446	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	2.08	CHEMBL2116	Homo sapiens	Inhibition	%	2.08
	8079588	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.83	CHEMBL2116	Homo sapiens	Inhibition	%	0.83
	8079951	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	3.42	CHEMBL2116	Homo sapiens	Inhibition	%	3.42
	8080056	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	2.64	CHEMBL2116	Homo sapiens	Inhibition	%	2.64
	8080308	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	5.83	CHEMBL2116	Homo sapiens	Inhibition	%	5.83
	8080532	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	36.3	CHEMBL2116	Homo sapiens	Inhibition	%	36.3
	8080647	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.53	CHEMBL2116	Homo sapiens	Inhibition	%	0.53
	8081035	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-1.29	CHEMBL2116	Homo sapiens	Inhibition	%	-1.29
	8081170	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1	Outside typical range	CHEMBL1909391	=	Inhibition	%	-23.14	CHEMBL2116	Homo sapiens	Inhibition	%	-23.14
	8081538	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	13.22	CHEMBL2116	Homo sapiens	Inhibition	%	13.22
	8081641	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	0.44	CHEMBL2116	Homo sapiens	Inhibition	%	0.44
	8081865	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	11.04	CHEMBL2116	Homo sapiens	Inhibition	%	11.04
	8082117	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-0.2	CHEMBL2116	Homo sapiens	Inhibition	%	-0.2
	8082230	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	2.09	CHEMBL2116	Homo sapiens	Inhibition	%	2.09
	8082454	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	-1.23	CHEMBL2116	Homo sapiens	Inhibition	%	-1.23
	8082627	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-2.2	CHEMBL2116	Homo sapiens	Inhibition	%	-2.2
	8082750	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.35	CHEMBL2116	Homo sapiens	Inhibition	%	1.35
	8082974	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.57	CHEMBL2116	Homo sapiens	Inhibition	%	0.57
	8083130	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	5.78	CHEMBL2116	Homo sapiens	Inhibition	%	5.78
	8083453	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-0.32	CHEMBL2116	Homo sapiens	Inhibition	%	-0.32
	8083707	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	3.46	CHEMBL2116	Homo sapiens	Inhibition	%	3.46
	8084041	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	3.56	CHEMBL2116	Homo sapiens	Inhibition	%	3.56
	8084226	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	28.88	CHEMBL2116	Homo sapiens	Inhibition	%	28.88
	8084568	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.84	CHEMBL2116	Homo sapiens	Inhibition	%	1.84
	8084729	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	26.31	CHEMBL2116	Homo sapiens	Inhibition	%	26.31
	8085051	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	6.02	CHEMBL2116	Homo sapiens	Inhibition	%	6.02
	8085307	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-2.17	CHEMBL2116	Homo sapiens	Inhibition	%	-2.17
	8085639	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	-0.33	CHEMBL2116	Homo sapiens	Inhibition	%	-0.33
	8085828	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	62.22	CHEMBL2116	Homo sapiens	Inhibition	%	62.22
	8086167	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	2.49	CHEMBL2116	Homo sapiens	Inhibition	%	2.49
	8086329	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	3.96	CHEMBL2116	Homo sapiens	Inhibition	%	3.96
	8086553	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	10.22	CHEMBL2116	Homo sapiens	Inhibition	%	10.22
	8086652	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-1.16	CHEMBL2116	Homo sapiens	Inhibition	%	-1.16
	8086863	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	6.15	CHEMBL2116	Homo sapiens	Inhibition	%	6.15
	8087087	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	1.77	CHEMBL2116	Homo sapiens	Inhibition	%	1.77
	8087245	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	4.95	CHEMBL2116	Homo sapiens	Inhibition	%	4.95
	8087583	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	3.16	CHEMBL2116	Homo sapiens	Inhibition	%	3.16
	8087721	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.56	CHEMBL2116	Homo sapiens	Inhibition	%	4.56
	8087945	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	2.07	CHEMBL2116	Homo sapiens	Inhibition	%	2.07
	8088087	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	3.25	CHEMBL2116	Homo sapiens	Inhibition	%	3.25
	8088235	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	5.24	CHEMBL2116	Homo sapiens	Inhibition	%	5.24
	8088459	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.49	CHEMBL2116	Homo sapiens	Inhibition	%	1.49
	8088587	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	1.04	CHEMBL2116	Homo sapiens	Inhibition	%	1.04
	8088904	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	4.49	CHEMBL2116	Homo sapiens	Inhibition	%	4.49
	8089256	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	6.28	CHEMBL2116	Homo sapiens	Inhibition	%	6.28
	8089404	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	3.74	CHEMBL2116	Homo sapiens	Inhibition	%	3.74
	8089748	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	-1.8	CHEMBL2116	Homo sapiens	Inhibition	%	-1.8
	8089928	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.34	CHEMBL2116	Homo sapiens	Inhibition	%	0.34
	8090317	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	3.18	CHEMBL2116	Homo sapiens	Inhibition	%	3.18
	8090484	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	3.08	CHEMBL2116	Homo sapiens	Inhibition	%	3.08
	8090847	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	-1.16	CHEMBL2116	Homo sapiens	Inhibition	%	-1.16
	8091052	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	2.07	CHEMBL2116	Homo sapiens	Inhibition	%	2.07
	8091413	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	8.68	CHEMBL2116	Homo sapiens	Inhibition	%	8.68
	8091568	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.49	CHEMBL2116	Homo sapiens	Inhibition	%	2.49
	8091908	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	4.09	CHEMBL2116	Homo sapiens	Inhibition	%	4.09
	8092269	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-1.95	CHEMBL2116	Homo sapiens	Inhibition	%	-1.95
	8092420	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	5.96	CHEMBL2116	Homo sapiens	Inhibition	%	5.96
	8092792	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	2.89	CHEMBL2116	Homo sapiens	Inhibition	%	2.89
	8092921	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	5.06	CHEMBL2116	Homo sapiens	Inhibition	%	5.06
	8093145	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	2.54	CHEMBL2116	Homo sapiens	Inhibition	%	2.54
	8093233	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	-0.71	CHEMBL2116	Homo sapiens	Inhibition	%	-0.71
	8093597	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	4.59	CHEMBL2116	Homo sapiens	Inhibition	%	4.59
	8093736	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	40.18	CHEMBL2116	Homo sapiens	Inhibition	%	40.18
	8093960	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-4.37	CHEMBL2116	Homo sapiens	Inhibition	%	-4.37
	8094080	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	2.95	CHEMBL2116	Homo sapiens	Inhibition	%	2.95
	8094260	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.25	CHEMBL2116	Homo sapiens	Inhibition	%	0.25
	8094484	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	2.58	CHEMBL2116	Homo sapiens	Inhibition	%	2.58
	8094659	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	6.34	CHEMBL2116	Homo sapiens	Inhibition	%	6.34
	8094815	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	4.91	CHEMBL2116	Homo sapiens	Inhibition	%	4.91
	8095039	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	3.81	CHEMBL2116	Homo sapiens	Inhibition	%	3.81
	8095179	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	2.41	CHEMBL2116	Homo sapiens	Inhibition	%	2.41
	8095382	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	4.61	CHEMBL2116	Homo sapiens	Inhibition	%	4.61
	8095606	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.36	CHEMBL2116	Homo sapiens	Inhibition	%	0.36
	8095747	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	14.5	CHEMBL2116	Homo sapiens	Inhibition	%	14.5
	8095895	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	5.92	CHEMBL2116	Homo sapiens	Inhibition	%	5.92
	8096119	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	3.91	CHEMBL2116	Homo sapiens	Inhibition	%	3.91
	8096236	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.92	CHEMBL2116	Homo sapiens	Inhibition	%	3.92
	8096599	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	2.56	CHEMBL2116	Homo sapiens	Inhibition	%	2.56
	8096755	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	3.11	CHEMBL2116	Homo sapiens	Inhibition	%	3.11
	8096979	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	7.48	CHEMBL2116	Homo sapiens	Inhibition	%	7.48
	8097126	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.62	CHEMBL2116	Homo sapiens	Inhibition	%	0.62
	8097433	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	3.17	CHEMBL2116	Homo sapiens	Inhibition	%	3.17
	8097657	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	0.02	CHEMBL2116	Homo sapiens	Inhibition	%	0.02
	8097807	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	21.06	CHEMBL2116	Homo sapiens	Inhibition	%	21.06
	8098164	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	2.8	CHEMBL2116	Homo sapiens	Inhibition	%	2.8
	8098284	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.66	CHEMBL2116	Homo sapiens	Inhibition	%	-0.66
	8098688	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-2.52	CHEMBL2116	Homo sapiens	Inhibition	%	-2.52
	8098873	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	13.25	CHEMBL2116	Homo sapiens	Inhibition	%	13.25
	8099241	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	4.29	CHEMBL2116	Homo sapiens	Inhibition	%	4.29
	8099383	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	-0.02	CHEMBL2116	Homo sapiens	Inhibition	%	-0.02
	8099801	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	1.42	CHEMBL2116	Homo sapiens	Inhibition	%	1.42
	8099948	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	7.16	CHEMBL2116	Homo sapiens	Inhibition	%	7.16
	8100318	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	5.38	CHEMBL2116	Homo sapiens	Inhibition	%	5.38
	8100434	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.9	CHEMBL2116	Homo sapiens	Inhibition	%	3.9
	8100658	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	3.09	CHEMBL2116	Homo sapiens	Inhibition	%	3.09
	8100798	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	1.22	CHEMBL2116	Homo sapiens	Inhibition	%	1.22
	8101182	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	4.51	CHEMBL2116	Homo sapiens	Inhibition	%	4.51
	8101324	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	5.0	CHEMBL2116	Homo sapiens	Inhibition	%	5.0
	8101733	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	1.17	CHEMBL2116	Homo sapiens	Inhibition	%	1.17
	8101986	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	7.68	CHEMBL2116	Homo sapiens	Inhibition	%	7.68
	8102141	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	2.4	CHEMBL2116	Homo sapiens	Inhibition	%	2.4
	8102496	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	-5.76	CHEMBL2116	Homo sapiens	Inhibition	%	-5.76
	8102616	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	1.39	CHEMBL2116	Homo sapiens	Inhibition	%	1.39
	8102840	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.63	CHEMBL2116	Homo sapiens	Inhibition	%	0.63
	8103018	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	3.28	CHEMBL2116	Homo sapiens	Inhibition	%	3.28
	8103214	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	4.97	CHEMBL2116	Homo sapiens	Inhibition	%	4.97
	8103576	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	1.99	CHEMBL2116	Homo sapiens	Inhibition	%	1.99
	8103726	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.21	CHEMBL2116	Homo sapiens	Inhibition	%	2.21
	8103950	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	0.14	CHEMBL2116	Homo sapiens	Inhibition	%	0.14
	8104135	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	1.29	CHEMBL2116	Homo sapiens	Inhibition	%	1.29
	8104283	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	6.0	CHEMBL2116	Homo sapiens	Inhibition	%	6.0
	8104507	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	8.96	CHEMBL2116	Homo sapiens	Inhibition	%	8.96
	8104653	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	11.83	CHEMBL2116	Homo sapiens	Inhibition	%	11.83
	8104991	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	3.23	CHEMBL2116	Homo sapiens	Inhibition	%	3.23
	8105131	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	2.52	CHEMBL2116	Homo sapiens	Inhibition	%	2.52
	8105521	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	5.98	CHEMBL2116	Homo sapiens	Inhibition	%	5.98
	8105659	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	5.35	CHEMBL2116	Homo sapiens	Inhibition	%	5.35
	8105883	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	2.86	CHEMBL2116	Homo sapiens	Inhibition	%	2.86
	8105939	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	2.44	CHEMBL2116	Homo sapiens	Inhibition	%	2.44
	8106163	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	2.19	CHEMBL2116	Homo sapiens	Inhibition	%	2.19
	8106328	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	0.22	CHEMBL2116	Homo sapiens	Inhibition	%	0.22
	8106484	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	10.97	CHEMBL2116	Homo sapiens	Inhibition	%	10.97
	8106708	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	2.63	CHEMBL2116	Homo sapiens	Inhibition	%	2.63
	8106837	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	0.95	CHEMBL2116	Homo sapiens	Inhibition	%	0.95
	8107182	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	2.24	CHEMBL2116	Homo sapiens	Inhibition	%	2.24
	8107354	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	2.18	CHEMBL2116	Homo sapiens	Inhibition	%	2.18
	8107555	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	14.98	CHEMBL2116	Homo sapiens	Inhibition	%	14.98
	8107779	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	4.67	CHEMBL2116	Homo sapiens	Inhibition	%	4.67
	8107914	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	3.97	CHEMBL2116	Homo sapiens	Inhibition	%	3.97
	8108296	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	-1.59	CHEMBL2116	Homo sapiens	Inhibition	%	-1.59
	8108471	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	2.32	CHEMBL2116	Homo sapiens	Inhibition	%	2.32
	8108842	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	13.7	CHEMBL2116	Homo sapiens	Inhibition	%	13.7
	8108984	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	4.55	CHEMBL2116	Homo sapiens	Inhibition	%	4.55
	8109322	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	4.56	CHEMBL2116	Homo sapiens	Inhibition	%	4.56
	8109452	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.55	CHEMBL2116	Homo sapiens	Inhibition	%	0.55
	8109676	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	3.01	CHEMBL2116	Homo sapiens	Inhibition	%	3.01
	8109847	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	9.02	CHEMBL2116	Homo sapiens	Inhibition	%	9.02
	8110203	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	8.23	CHEMBL2116	Homo sapiens	Inhibition	%	8.23
	8110482	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	3.32	CHEMBL2116	Homo sapiens	Inhibition	%	3.32
	8110648	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	2.79	CHEMBL2116	Homo sapiens	Inhibition	%	2.79
	8111030	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	2.16	CHEMBL2116	Homo sapiens	Inhibition	%	2.16
	8111153	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-5.13	CHEMBL2116	Homo sapiens	Inhibition	%	-5.13
	8111504	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	0.91	CHEMBL2116	Homo sapiens	Inhibition	%	0.91
	8111670	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	4.05	CHEMBL2116	Homo sapiens	Inhibition	%	4.05
	8111894	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	6.91	CHEMBL2116	Homo sapiens	Inhibition	%	6.91
	8112099	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	6.16	CHEMBL2116	Homo sapiens	Inhibition	%	6.16
	8112236	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	2.15	CHEMBL2116	Homo sapiens	Inhibition	%	2.15
	8112460	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	1.4	CHEMBL2116	Homo sapiens	Inhibition	%	1.4
	8112628	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	0.92	CHEMBL2116	Homo sapiens	Inhibition	%	0.92
	8112800	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.46	CHEMBL2116	Homo sapiens	Inhibition	%	0.46
	8113176	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	4.37	CHEMBL2116	Homo sapiens	Inhibition	%	4.37
	8113312	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.68	CHEMBL2116	Homo sapiens	Inhibition	%	1.68
	8113536	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	3.82	CHEMBL2116	Homo sapiens	Inhibition	%	3.82
	8113660	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	4.95	CHEMBL2116	Homo sapiens	Inhibition	%	4.95
	8114000	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-2.91	CHEMBL2116	Homo sapiens	Inhibition	%	-2.91
	8114176	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	6.24	CHEMBL2116	Homo sapiens	Inhibition	%	6.24
	8114532	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	4.1	CHEMBL2116	Homo sapiens	Inhibition	%	4.1
	8114808	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.51	CHEMBL2116	Homo sapiens	Inhibition	%	1.51
	8114974	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	-0.22	CHEMBL2116	Homo sapiens	Inhibition	%	-0.22
	8115198	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	0.27	CHEMBL2116	Homo sapiens	Inhibition	%	0.27
	8115363	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-1.09	CHEMBL2116	Homo sapiens	Inhibition	%	-1.09
	8115483	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-0.72	CHEMBL2116	Homo sapiens	Inhibition	%	-0.72
	8115707	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-4.68	CHEMBL2116	Homo sapiens	Inhibition	%	-4.68
	8115840	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	4.25	CHEMBL2116	Homo sapiens	Inhibition	%	4.25
	8116223	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	33.68	CHEMBL2116	Homo sapiens	Inhibition	%	33.68
	8116426	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	12.13	CHEMBL2116	Homo sapiens	Inhibition	%	12.13
	8116784	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	1.03	CHEMBL2116	Homo sapiens	Inhibition	%	1.03
	8116956	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	4.34	CHEMBL2116	Homo sapiens	Inhibition	%	4.34
	8117127	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	1.14	CHEMBL2116	Homo sapiens	Inhibition	%	1.14
	8117351	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	3.2	CHEMBL2116	Homo sapiens	Inhibition	%	3.2
	8117509	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	3.94	CHEMBL2116	Homo sapiens	Inhibition	%	3.94
	8117863	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.49	CHEMBL2116	Homo sapiens	Inhibition	%	0.49
	8118001	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	3.75	CHEMBL2116	Homo sapiens	Inhibition	%	3.75
	8118341	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	7.86	CHEMBL2116	Homo sapiens	Inhibition	%	7.86
	8118513	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	3.3	CHEMBL2116	Homo sapiens	Inhibition	%	3.3
	8118737	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	5.76	CHEMBL2116	Homo sapiens	Inhibition	%	5.76
	8118873	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	5.24	CHEMBL2116	Homo sapiens	Inhibition	%	5.24
	8119144	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	1.06	CHEMBL2116	Homo sapiens	Inhibition	%	1.06
	8119527	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	0.75	CHEMBL2116	Homo sapiens	Inhibition	%	0.75
	8119694	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-0.66	CHEMBL2116	Homo sapiens	Inhibition	%	-0.66
	8120037	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.32	CHEMBL2116	Homo sapiens	Inhibition	%	1.32
	8120176	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.13	CHEMBL2116	Homo sapiens	Inhibition	%	0.13
	8120400	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.71	CHEMBL2116	Homo sapiens	Inhibition	%	1.71
	8120560	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	2.29	CHEMBL2116	Homo sapiens	Inhibition	%	2.29
	8120761	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	43.27	CHEMBL2116	Homo sapiens	Inhibition	%	43.27
	8121113	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.27	CHEMBL2116	Homo sapiens	Inhibition	%	0.27
	8121285	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	-0.29	CHEMBL2116	Homo sapiens	Inhibition	%	-0.29
	8121676	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	11.62	CHEMBL2116	Homo sapiens	Inhibition	%	11.62
	8121839	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	7.19	CHEMBL2116	Homo sapiens	Inhibition	%	7.19
	8122184	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	3.36	CHEMBL2116	Homo sapiens	Inhibition	%	3.36
	8122322	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	4.77	CHEMBL2116	Homo sapiens	Inhibition	%	4.77
	8122546	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	14.42	CHEMBL2116	Homo sapiens	Inhibition	%	14.42
	8122666	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	3.24	CHEMBL2116	Homo sapiens	Inhibition	%	3.24
	8123057	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	4.17	CHEMBL2116	Homo sapiens	Inhibition	%	4.17
	8123199	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	2.61	CHEMBL2116	Homo sapiens	Inhibition	%	2.61
	8123477	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	4.27	CHEMBL2116	Homo sapiens	Inhibition	%	4.27
	8123851	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	6.79	CHEMBL2116	Homo sapiens	Inhibition	%	6.79
	8124018	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-1.1	CHEMBL2116	Homo sapiens	Inhibition	%	-1.1
	8124361	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	-3.44	CHEMBL2116	Homo sapiens	Inhibition	%	-3.44
	8124724	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	1.6	CHEMBL2116	Homo sapiens	Inhibition	%	1.6
	8124889	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	3.11	CHEMBL2116	Homo sapiens	Inhibition	%	3.11
	8125090	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	5.08	CHEMBL2116	Homo sapiens	Inhibition	%	5.08
	8125314	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	7.27	CHEMBL2116	Homo sapiens	Inhibition	%	7.27
	8125444	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.65	CHEMBL2116	Homo sapiens	Inhibition	%	0.65
	8125612	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.84	CHEMBL2116	Homo sapiens	Inhibition	%	1.84
	8125836	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.68	CHEMBL2116	Homo sapiens	Inhibition	%	0.68
	8126000	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	1.01	CHEMBL2116	Homo sapiens	Inhibition	%	1.01
	8126164	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	4.98	CHEMBL2116	Homo sapiens	Inhibition	%	4.98
	8126388	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	7.01	CHEMBL2116	Homo sapiens	Inhibition	%	7.01
	8126503	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-2.18	CHEMBL2116	Homo sapiens	Inhibition	%	-2.18
	8126863	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	42.78	CHEMBL2116	Homo sapiens	Inhibition	%	42.78
	8126985	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	8.18	CHEMBL2116	Homo sapiens	Inhibition	%	8.18
	8127209	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	3.68	CHEMBL2116	Homo sapiens	Inhibition	%	3.68
	8127376	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	7.22	CHEMBL2116	Homo sapiens	Inhibition	%	7.22
	8127518	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	6.24	CHEMBL2116	Homo sapiens	Inhibition	%	6.24
	8127742	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	2.97	CHEMBL2116	Homo sapiens	Inhibition	%	2.97
	8127806	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	0.57	CHEMBL2116	Homo sapiens	Inhibition	%	0.57
	8128030	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	7.86	CHEMBL2116	Homo sapiens	Inhibition	%	7.86
	8128182	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.57	CHEMBL2116	Homo sapiens	Inhibition	%	1.57
	8128349	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	1.47	CHEMBL2116	Homo sapiens	Inhibition	%	1.47
	8128573	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	-2.07	CHEMBL2116	Homo sapiens	Inhibition	%	-2.07
	8128692	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	7.99	CHEMBL2116	Homo sapiens	Inhibition	%	7.99
	8129053	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	4.91	CHEMBL2116	Homo sapiens	Inhibition	%	4.91
	8129224	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.73	CHEMBL2116	Homo sapiens	Inhibition	%	0.73
	8129637	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	3.27	CHEMBL2116	Homo sapiens	Inhibition	%	3.27
	8129776	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.41	CHEMBL2116	Homo sapiens	Inhibition	%	0.41
	8130161	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	2.02	CHEMBL2116	Homo sapiens	Inhibition	%	2.02
	8130333	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	3.06	CHEMBL2116	Homo sapiens	Inhibition	%	3.06
	8130717	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	12.74	CHEMBL2116	Homo sapiens	Inhibition	%	12.74
	8130833	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.06	CHEMBL2116	Homo sapiens	Inhibition	%	2.06
	8131057	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	3.41	CHEMBL2116	Homo sapiens	Inhibition	%	3.41
	8131196	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	4.16	CHEMBL2116	Homo sapiens	Inhibition	%	4.16
	8131540	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	6.3	CHEMBL2116	Homo sapiens	Inhibition	%	6.3
	8131707	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	5.58	CHEMBL2116	Homo sapiens	Inhibition	%	5.58
	8132072	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	5.34	CHEMBL2116	Homo sapiens	Inhibition	%	5.34
	8132358	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-0.28	CHEMBL2116	Homo sapiens	Inhibition	%	-0.28
	8132505	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	4.38	CHEMBL2116	Homo sapiens	Inhibition	%	4.38
	8132897	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	-0.38	CHEMBL2116	Homo sapiens	Inhibition	%	-0.38
	8133018	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	-4.66	CHEMBL2116	Homo sapiens	Inhibition	%	-4.66
	8133242	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.84	CHEMBL2116	Homo sapiens	Inhibition	%	0.84
	8133380	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	2.36	CHEMBL2116	Homo sapiens	Inhibition	%	2.36
	8133552	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.01	CHEMBL2116	Homo sapiens	Inhibition	%	0.01
	8133776	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	1.26	CHEMBL2116	Homo sapiens	Inhibition	%	1.26
	8133956	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	7.01	CHEMBL2116	Homo sapiens	Inhibition	%	7.01
	8134104	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	0.21	CHEMBL2116	Homo sapiens	Inhibition	%	0.21
	8134328	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-2.04	CHEMBL2116	Homo sapiens	Inhibition	%	-2.04
	8134488	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	-0.17	CHEMBL2116	Homo sapiens	Inhibition	%	-0.17
	8134672	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-0.35	CHEMBL2116	Homo sapiens	Inhibition	%	-0.35
	8134896	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	4.21	CHEMBL2116	Homo sapiens	Inhibition	%	4.21
	8135056	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	6.43	CHEMBL2116	Homo sapiens	Inhibition	%	6.43
	8135395	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	-6.64	CHEMBL2116	Homo sapiens	Inhibition	%	-6.64
	8135536	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	7.3	CHEMBL2116	Homo sapiens	Inhibition	%	7.3
	8135881	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-0.1	CHEMBL2116	Homo sapiens	Inhibition	%	-0.1
	8136049	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	5.39	CHEMBL2116	Homo sapiens	Inhibition	%	5.39
	8136273	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	2.83	CHEMBL2116	Homo sapiens	Inhibition	%	2.83
	8136417	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	3.86	CHEMBL2116	Homo sapiens	Inhibition	%	3.86
	8136707	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	3.07	CHEMBL2116	Homo sapiens	Inhibition	%	3.07
	8136842	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	1.12	CHEMBL2116	Homo sapiens	Inhibition	%	1.12
	8137066	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	7.05	CHEMBL2116	Homo sapiens	Inhibition	%	7.05
	8137229	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	-1.29	CHEMBL2116	Homo sapiens	Inhibition	%	-1.29
	8137573	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-4.03	CHEMBL2116	Homo sapiens	Inhibition	%	-4.03
	8137721	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	5.17	CHEMBL2116	Homo sapiens	Inhibition	%	5.17
	8138111	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	0.55	CHEMBL2116	Homo sapiens	Inhibition	%	0.55
	8138290	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	3.05	CHEMBL2116	Homo sapiens	Inhibition	%	3.05
	8138662	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-0.98	CHEMBL2116	Homo sapiens	Inhibition	%	-0.98
	8138820	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.09	CHEMBL2116	Homo sapiens	Inhibition	%	1.09
	8139229	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	6.97	CHEMBL2116	Homo sapiens	Inhibition	%	6.97
	8139388	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	3.78	CHEMBL2116	Homo sapiens	Inhibition	%	3.78
	8139726	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	3.87	CHEMBL2116	Homo sapiens	Inhibition	%	3.87
	8139867	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	5.66	CHEMBL2116	Homo sapiens	Inhibition	%	5.66
	8140091	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	5.75	CHEMBL2116	Homo sapiens	Inhibition	%	5.75
	8140214	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	7.56	CHEMBL2116	Homo sapiens	Inhibition	%	7.56
	8140597	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	6.28	CHEMBL2116	Homo sapiens	Inhibition	%	6.28
	8140740	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	4.45	CHEMBL2116	Homo sapiens	Inhibition	%	4.45
	8141042	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	-1.68	CHEMBL2116	Homo sapiens	Inhibition	%	-1.68
	8141396	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	1.32	CHEMBL2116	Homo sapiens	Inhibition	%	1.32
	8141556	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	2.07	CHEMBL2116	Homo sapiens	Inhibition	%	2.07
	8141899	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.33	CHEMBL2116	Homo sapiens	Inhibition	%	0.33
	8142060	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.54	CHEMBL2116	Homo sapiens	Inhibition	%	0.54
	8142284	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.38	CHEMBL2116	Homo sapiens	Inhibition	%	0.38
	8142452	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	2.88	CHEMBL2116	Homo sapiens	Inhibition	%	2.88
	8142628	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	2.15	CHEMBL2116	Homo sapiens	Inhibition	%	2.15
	8142852	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	2.49	CHEMBL2116	Homo sapiens	Inhibition	%	2.49
	8143001	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-5.48	CHEMBL2116	Homo sapiens	Inhibition	%	-5.48
	8143156	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	-0.27	CHEMBL2116	Homo sapiens	Inhibition	%	-0.27
	8143380	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	2.03	CHEMBL2116	Homo sapiens	Inhibition	%	2.03
	8143567	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	3.18	CHEMBL2116	Homo sapiens	Inhibition	%	3.18
	8143726	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	5.96	CHEMBL2116	Homo sapiens	Inhibition	%	5.96
	8143950	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.47	CHEMBL2116	Homo sapiens	Inhibition	%	3.47
	8144064	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.41	CHEMBL2116	Homo sapiens	Inhibition	%	1.41
	8144427	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	4.13	CHEMBL2116	Homo sapiens	Inhibition	%	4.13
	8144557	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	1.74	CHEMBL2116	Homo sapiens	Inhibition	%	1.74
	8144934	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	2.93	CHEMBL2116	Homo sapiens	Inhibition	%	2.93
	8145071	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	3.89	CHEMBL2116	Homo sapiens	Inhibition	%	3.89
	8145295	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	4.37	CHEMBL2116	Homo sapiens	Inhibition	%	4.37
	8145384	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	3.8	CHEMBL2116	Homo sapiens	Inhibition	%	3.8
	8145732	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	3.94	CHEMBL2116	Homo sapiens	Inhibition	%	3.94
	8145893	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	-0.21	CHEMBL2116	Homo sapiens	Inhibition	%	-0.21
	8146117	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	3.21	CHEMBL2116	Homo sapiens	Inhibition	%	3.21
	8146237	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-4.11	CHEMBL2116	Homo sapiens	Inhibition	%	-4.11
	8146621	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	0.93	CHEMBL2116	Homo sapiens	Inhibition	%	0.93
	8146788	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	14.03	CHEMBL2116	Homo sapiens	Inhibition	%	14.03
	8147181	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	5.07	CHEMBL2116	Homo sapiens	Inhibition	%	5.07
	8147323	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	-0.41	CHEMBL2116	Homo sapiens	Inhibition	%	-0.41
	8147700	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.06	CHEMBL2116	Homo sapiens	Inhibition	%	1.06
	8147887	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	8.21	CHEMBL2116	Homo sapiens	Inhibition	%	8.21
	8148269	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	7.1	CHEMBL2116	Homo sapiens	Inhibition	%	7.1
	8148383	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-0.88	CHEMBL2116	Homo sapiens	Inhibition	%	-0.88
	8148746	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	5.9	CHEMBL2116	Homo sapiens	Inhibition	%	5.9
	8148884	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	7.31	CHEMBL2116	Homo sapiens	Inhibition	%	7.31
	8149108	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	3.28	CHEMBL2116	Homo sapiens	Inhibition	%	3.28
	8149267	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	3.89	CHEMBL2116	Homo sapiens	Inhibition	%	3.89
	8149625	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	2.58	CHEMBL2116	Homo sapiens	Inhibition	%	2.58
	8149723	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	-0.38	CHEMBL2116	Homo sapiens	Inhibition	%	-0.38
	8149947	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	2.44	CHEMBL2116	Homo sapiens	Inhibition	%	2.44
	8150072	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	1.95	CHEMBL2116	Homo sapiens	Inhibition	%	1.95
	8150456	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-3.97	CHEMBL2116	Homo sapiens	Inhibition	%	-3.97
	8150576	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	1.29	CHEMBL2116	Homo sapiens	Inhibition	%	1.29
	8150800	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-4.16	CHEMBL2116	Homo sapiens	Inhibition	%	-4.16
	8150965	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	2.09	CHEMBL2116	Homo sapiens	Inhibition	%	2.09
	8151128	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	0.12	CHEMBL2116	Homo sapiens	Inhibition	%	0.12
	8151529	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.14	CHEMBL2116	Homo sapiens	Inhibition	%	2.14
	8151667	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	2.89	CHEMBL2116	Homo sapiens	Inhibition	%	2.89
	8151891	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.22	CHEMBL2116	Homo sapiens	Inhibition	%	0.22
	8152045	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	3.96	CHEMBL2116	Homo sapiens	Inhibition	%	3.96
	8152233	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	4.79	CHEMBL2116	Homo sapiens	Inhibition	%	4.79
	8152615	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	0.19	CHEMBL2116	Homo sapiens	Inhibition	%	0.19
	8152729	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.9	CHEMBL2116	Homo sapiens	Inhibition	%	2.9
	8152953	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	3.91	CHEMBL2116	Homo sapiens	Inhibition	%	3.91
	8153092	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.72	CHEMBL2116	Homo sapiens	Inhibition	%	3.72
	8153453	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	8.15	CHEMBL2116	Homo sapiens	Inhibition	%	8.15
	8153610	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-0.61	CHEMBL2116	Homo sapiens	Inhibition	%	-0.61
	8153967	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	4.46	CHEMBL2116	Homo sapiens	Inhibition	%	4.46
	8154288	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	0.31	CHEMBL2116	Homo sapiens	Inhibition	%	0.31
	8154414	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	3.81	CHEMBL2116	Homo sapiens	Inhibition	%	3.81
	8154638	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	1.83	CHEMBL2116	Homo sapiens	Inhibition	%	1.83
	8154797	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	1.89	CHEMBL2116	Homo sapiens	Inhibition	%	1.89
	8155141	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-0.32	CHEMBL2116	Homo sapiens	Inhibition	%	-0.32
	8155317	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.94	CHEMBL2116	Homo sapiens	Inhibition	%	0.94
	8155478	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-3.42	CHEMBL2116	Homo sapiens	Inhibition	%	-3.42
	8155702	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	5.43	CHEMBL2116	Homo sapiens	Inhibition	%	5.43
	8155880	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.42	CHEMBL2116	Homo sapiens	Inhibition	%	2.42
	8156242	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	2.74	CHEMBL2116	Homo sapiens	Inhibition	%	2.74
	8156454	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	2.34	CHEMBL2116	Homo sapiens	Inhibition	%	2.34
	8156604	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	3.65	CHEMBL2116	Homo sapiens	Inhibition	%	3.65
	8156828	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	0.93	CHEMBL2116	Homo sapiens	Inhibition	%	0.93
	8156971	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	9.24	CHEMBL2116	Homo sapiens	Inhibition	%	9.24
	8157315	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	7.41	CHEMBL2116	Homo sapiens	Inhibition	%	7.41
	8157456	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	5.38	CHEMBL2116	Homo sapiens	Inhibition	%	5.38
	8157810	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	1.85	CHEMBL2116	Homo sapiens	Inhibition	%	1.85
	8157971	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.37	CHEMBL2116	Homo sapiens	Inhibition	%	2.37
	8158195	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	2.94	CHEMBL2116	Homo sapiens	Inhibition	%	2.94
	8158445	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	4.72	CHEMBL2116	Homo sapiens	Inhibition	%	4.72
	8158603	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	8.93	CHEMBL2116	Homo sapiens	Inhibition	%	8.93
	8158996	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	9.82	CHEMBL2116	Homo sapiens	Inhibition	%	9.82
	8159131	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	4.18	CHEMBL2116	Homo sapiens	Inhibition	%	4.18
	8159475	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	3.93	CHEMBL2116	Homo sapiens	Inhibition	%	3.93
	8159606	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	9.57	CHEMBL2116	Homo sapiens	Inhibition	%	9.57
	8159830	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	4.5	CHEMBL2116	Homo sapiens	Inhibition	%	4.5
	8159971	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	3.64	CHEMBL2116	Homo sapiens	Inhibition	%	3.64
	8160332	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	2.26	CHEMBL2116	Homo sapiens	Inhibition	%	2.26
	8160482	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.71	CHEMBL2116	Homo sapiens	Inhibition	%	0.71
	8160776	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	5.09	CHEMBL2116	Homo sapiens	Inhibition	%	5.09
	8161150	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	4.4	CHEMBL2116	Homo sapiens	Inhibition	%	4.4
	8161293	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	1.53	CHEMBL2116	Homo sapiens	Inhibition	%	1.53
	8161642	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	-0.21	CHEMBL2116	Homo sapiens	Inhibition	%	-0.21
	8161780	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	25.01	CHEMBL2116	Homo sapiens	Inhibition	%	25.01
	8162004	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	2.4	CHEMBL2116	Homo sapiens	Inhibition	%	2.4
	8162134	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	5.49	CHEMBL2116	Homo sapiens	Inhibition	%	5.49
	8162518	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	3.1	CHEMBL2116	Homo sapiens	Inhibition	%	3.1
	8162771	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	6.01	CHEMBL2116	Homo sapiens	Inhibition	%	6.01
	8162919	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	24.0	CHEMBL2116	Homo sapiens	Inhibition	%	24.0
	8163143	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	53.42	CHEMBL2116	Homo sapiens	Inhibition	%	53.42
	8163312	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	3.83	CHEMBL2116	Homo sapiens	Inhibition	%	3.83
	8163446	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	2.14	CHEMBL2116	Homo sapiens	Inhibition	%	2.14
	8163670	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	4.08	CHEMBL2116	Homo sapiens	Inhibition	%	4.08
	8163793	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	4.29	CHEMBL2116	Homo sapiens	Inhibition	%	4.29
	8164151	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	10.66	CHEMBL2116	Homo sapiens	Inhibition	%	10.66
	8164291	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	3.69	CHEMBL2116	Homo sapiens	Inhibition	%	3.69
	8164670	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	2.03	CHEMBL2116	Homo sapiens	Inhibition	%	2.03
	8164814	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-1.6	CHEMBL2116	Homo sapiens	Inhibition	%	-1.6
	8165038	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	10.32	CHEMBL2116	Homo sapiens	Inhibition	%	10.32
	8165108	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	3.31	CHEMBL2116	Homo sapiens	Inhibition	%	3.31
	8165473	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	-0.82	CHEMBL2116	Homo sapiens	Inhibition	%	-0.82
	8165616	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	12.62	CHEMBL2116	Homo sapiens	Inhibition	%	12.62
	8165840	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-0.39	CHEMBL2116	Homo sapiens	Inhibition	%	-0.39
	8165966	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	4.22	CHEMBL2116	Homo sapiens	Inhibition	%	4.22
	8166328	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	10.95	CHEMBL2116	Homo sapiens	Inhibition	%	10.95
	8166458	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	3.23	CHEMBL2116	Homo sapiens	Inhibition	%	3.23
	8166682	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	4.6	CHEMBL2116	Homo sapiens	Inhibition	%	4.6
	8166783	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	5.95	CHEMBL2116	Homo sapiens	Inhibition	%	5.95
	8167095	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	2.76	CHEMBL2116	Homo sapiens	Inhibition	%	2.76
	8167460	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	6.92	CHEMBL2116	Homo sapiens	Inhibition	%	6.92
	8167624	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	5.58	CHEMBL2116	Homo sapiens	Inhibition	%	5.58
	8167981	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	3.56	CHEMBL2116	Homo sapiens	Inhibition	%	3.56
	8168105	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	3.59	CHEMBL2116	Homo sapiens	Inhibition	%	3.59
	8168329	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	5.96	CHEMBL2116	Homo sapiens	Inhibition	%	5.96
	8168470	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	3.45	CHEMBL2116	Homo sapiens	Inhibition	%	3.45
	8168606	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.53	CHEMBL2116	Homo sapiens	Inhibition	%	0.53
	8168830	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	3.53	CHEMBL2116	Homo sapiens	Inhibition	%	3.53
	8168994	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	12.52	CHEMBL2116	Homo sapiens	Inhibition	%	12.52
	8169360	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	39.99	CHEMBL2116	Homo sapiens	Inhibition	%	39.99
	8169440	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	8.1	CHEMBL2116	Homo sapiens	Inhibition	%	8.1
	8169664	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	23.85	CHEMBL2116	Homo sapiens	Inhibition	%	23.85
	8169798	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	3.61	CHEMBL2116	Homo sapiens	Inhibition	%	3.61
	8170167	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	4.79	CHEMBL2116	Homo sapiens	Inhibition	%	4.79
	8170292	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	0.95	CHEMBL2116	Homo sapiens	Inhibition	%	0.95
	8170516	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	4.04	CHEMBL2116	Homo sapiens	Inhibition	%	4.04
	8170656	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	3.32	CHEMBL2116	Homo sapiens	Inhibition	%	3.32
	8171015	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	2.35	CHEMBL2116	Homo sapiens	Inhibition	%	2.35
	8171212	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	2.15	CHEMBL2116	Homo sapiens	Inhibition	%	2.15
	8171429	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	3.43	CHEMBL2116	Homo sapiens	Inhibition	%	3.43
	8171794	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	7.54	CHEMBL2116	Homo sapiens	Inhibition	%	7.54
	8171947	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	4.7	CHEMBL2116	Homo sapiens	Inhibition	%	4.7
	8172303	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	4.32	CHEMBL2116	Homo sapiens	Inhibition	%	4.32
	8172655	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	2.92	CHEMBL2116	Homo sapiens	Inhibition	%	2.92
	8172797	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	4.65	CHEMBL2116	Homo sapiens	Inhibition	%	4.65
	8173157	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.49	CHEMBL2116	Homo sapiens	Inhibition	%	-0.49
	8173322	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	2.26	CHEMBL2116	Homo sapiens	Inhibition	%	2.26
	8173687	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	2.54	CHEMBL2116	Homo sapiens	Inhibition	%	2.54
	8173998	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	63.56	CHEMBL2116	Homo sapiens	Inhibition	%	63.56
	8174130	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	0.21	CHEMBL2116	Homo sapiens	Inhibition	%	0.21
	8174354	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	2.21	CHEMBL2116	Homo sapiens	Inhibition	%	2.21
	8174502	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.26	CHEMBL2116	Homo sapiens	Inhibition	%	0.26
	8174848	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.44	CHEMBL2116	Homo sapiens	Inhibition	%	0.44
	8174991	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	16.15	CHEMBL2116	Homo sapiens	Inhibition	%	16.15
	8175351	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	4.11	CHEMBL2116	Homo sapiens	Inhibition	%	4.11
	8175607	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	15.46	CHEMBL2116	Homo sapiens	Inhibition	%	15.46
	8175770	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.68	CHEMBL2116	Homo sapiens	Inhibition	%	2.68
	8175994	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	3.54	CHEMBL2116	Homo sapiens	Inhibition	%	3.54
	8176147	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	6.07	CHEMBL2116	Homo sapiens	Inhibition	%	6.07
	8176296	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	6.48	CHEMBL2116	Homo sapiens	Inhibition	%	6.48
	8176520	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	7.02	CHEMBL2116	Homo sapiens	Inhibition	%	7.02
	8176652	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	12.84	CHEMBL2116	Homo sapiens	Inhibition	%	12.84
	8177006	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	1.29	CHEMBL2116	Homo sapiens	Inhibition	%	1.29
	8177148	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	3.69	CHEMBL2116	Homo sapiens	Inhibition	%	3.69
	8177372	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	4.51	CHEMBL2116	Homo sapiens	Inhibition	%	4.51
	8177510	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	17.86	CHEMBL2116	Homo sapiens	Inhibition	%	17.86
	8177674	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	7.87	CHEMBL2116	Homo sapiens	Inhibition	%	7.87
	8177898	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	1.85	CHEMBL2116	Homo sapiens	Inhibition	%	1.85
	8178038	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	7.03	CHEMBL2116	Homo sapiens	Inhibition	%	7.03
	8178350	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.83	CHEMBL2116	Homo sapiens	Inhibition	%	1.83
	8178701	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	-0.09	CHEMBL2116	Homo sapiens	Inhibition	%	-0.09
	8178850	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.74	CHEMBL2116	Homo sapiens	Inhibition	%	1.74
	8179197	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	4.45	CHEMBL2116	Homo sapiens	Inhibition	%	4.45
	8179341	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	5.3	CHEMBL2116	Homo sapiens	Inhibition	%	5.3
	8179565	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	34.9	CHEMBL2116	Homo sapiens	Inhibition	%	34.9
	8179702	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	2.47	CHEMBL2116	Homo sapiens	Inhibition	%	2.47
	8179959	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	4.12	CHEMBL2116	Homo sapiens	Inhibition	%	4.12
	8180337	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	3.81	CHEMBL2116	Homo sapiens	Inhibition	%	3.81
	8180493	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	8.19	CHEMBL2116	Homo sapiens	Inhibition	%	8.19
	8180865	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	26.8	CHEMBL2116	Homo sapiens	Inhibition	%	26.8
	8180998	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	3.06	CHEMBL2116	Homo sapiens	Inhibition	%	3.06
	8181222	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	3.93	CHEMBL2116	Homo sapiens	Inhibition	%	3.93
	8181353	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	3.01	CHEMBL2116	Homo sapiens	Inhibition	%	3.01
	8181717	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	4.21	CHEMBL2116	Homo sapiens	Inhibition	%	4.21
	8181856	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	51.64	CHEMBL2116	Homo sapiens	Inhibition	%	51.64
	8182243	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	3.37	CHEMBL2116	Homo sapiens	Inhibition	%	3.37
	8182383	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.16	CHEMBL2116	Homo sapiens	Inhibition	%	1.16
	8182607	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	3.75	CHEMBL2116	Homo sapiens	Inhibition	%	3.75
	8182699	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	3.32	CHEMBL2116	Homo sapiens	Inhibition	%	3.32
	8183045	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	3.2	CHEMBL2116	Homo sapiens	Inhibition	%	3.2
	8183194	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	-0.63	CHEMBL2116	Homo sapiens	Inhibition	%	-0.63
	8183418	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	4.19	CHEMBL2116	Homo sapiens	Inhibition	%	4.19
	8183547	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	5.75	CHEMBL2116	Homo sapiens	Inhibition	%	5.75
	8183913	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	1.86	CHEMBL2116	Homo sapiens	Inhibition	%	1.86
	8184049	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	2.91	CHEMBL2116	Homo sapiens	Inhibition	%	2.91
	8184315	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	5.01	CHEMBL2116	Homo sapiens	Inhibition	%	5.01
	8184686	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	3.27	CHEMBL2116	Homo sapiens	Inhibition	%	3.27
	8184843	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	3.53	CHEMBL2116	Homo sapiens	Inhibition	%	3.53
	8185067	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	4.39	CHEMBL2116	Homo sapiens	Inhibition	%	4.39
	8185216	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	2.22	CHEMBL2116	Homo sapiens	Inhibition	%	2.22
	8185571	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	4.13	CHEMBL2116	Homo sapiens	Inhibition	%	4.13
	8185702	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	4.96	CHEMBL2116	Homo sapiens	Inhibition	%	4.96
	8186065	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	7.53	CHEMBL2116	Homo sapiens	Inhibition	%	7.53
	8186206	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	2.91	CHEMBL2116	Homo sapiens	Inhibition	%	2.91
	8186430	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	6.49	CHEMBL2116	Homo sapiens	Inhibition	%	6.49
	8186594	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	1.73	CHEMBL2116	Homo sapiens	Inhibition	%	1.73
	8186957	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	2.24	CHEMBL2116	Homo sapiens	Inhibition	%	2.24
	8187055	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	2.5	CHEMBL2116	Homo sapiens	Inhibition	%	2.5
	8187279	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	3.4	CHEMBL2116	Homo sapiens	Inhibition	%	3.4
	8187403	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	-7.0	CHEMBL2116	Homo sapiens	Inhibition	%	-7.0
	8187775	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.22	CHEMBL2116	Homo sapiens	Inhibition	%	0.22
	8187904	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	4.55	CHEMBL2116	Homo sapiens	Inhibition	%	4.55
	8188271	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	12.94	CHEMBL2116	Homo sapiens	Inhibition	%	12.94
	8188406	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	3.56	CHEMBL2116	Homo sapiens	Inhibition	%	3.56
	8188630	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	4.43	CHEMBL2116	Homo sapiens	Inhibition	%	4.43
	8188680	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.13	CHEMBL2116	Homo sapiens	Inhibition	%	4.13
	8188904	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	5.82	CHEMBL2116	Homo sapiens	Inhibition	%	5.82
	8189052	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	3.01	CHEMBL2116	Homo sapiens	Inhibition	%	3.01
	8189432	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	4.65	CHEMBL2116	Homo sapiens	Inhibition	%	4.65
	8189581	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	3.37	CHEMBL2116	Homo sapiens	Inhibition	%	3.37
	8189937	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	4.43	CHEMBL2116	Homo sapiens	Inhibition	%	4.43
	8190069	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	5.58	CHEMBL2116	Homo sapiens	Inhibition	%	5.58
	8190293	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	7.88	CHEMBL2116	Homo sapiens	Inhibition	%	7.88
	8190433	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	4.45	CHEMBL2116	Homo sapiens	Inhibition	%	4.45
	8190794	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	1.25	CHEMBL2116	Homo sapiens	Inhibition	%	1.25
	8190958	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	5.49	CHEMBL2116	Homo sapiens	Inhibition	%	5.49
	8191320	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	7.2	CHEMBL2116	Homo sapiens	Inhibition	%	7.2
	8191640	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	0.84	CHEMBL2116	Homo sapiens	Inhibition	%	0.84
	8191762	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	5.72	CHEMBL2116	Homo sapiens	Inhibition	%	5.72
	8192135	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	2.36	CHEMBL2116	Homo sapiens	Inhibition	%	2.36
	8192264	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	2.84	CHEMBL2116	Homo sapiens	Inhibition	%	2.84
	8192488	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	2.36	CHEMBL2116	Homo sapiens	Inhibition	%	2.36
	8192632	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	2.05	CHEMBL2116	Homo sapiens	Inhibition	%	2.05
	8192992	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	1.34	CHEMBL2116	Homo sapiens	Inhibition	%	1.34
	8193264	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.54	CHEMBL2116	Homo sapiens	Inhibition	%	2.54
	8193409	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	4.32	CHEMBL2116	Homo sapiens	Inhibition	%	4.32
	8193633	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	4.07	CHEMBL2116	Homo sapiens	Inhibition	%	4.07
	8193790	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	11.2	CHEMBL2116	Homo sapiens	Inhibition	%	11.2
	8193939	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-8.0	CHEMBL2116	Homo sapiens	Inhibition	%	-8.0
	8194163	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	0.77	CHEMBL2116	Homo sapiens	Inhibition	%	0.77
	8194294	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	3.32	CHEMBL2116	Homo sapiens	Inhibition	%	3.32
	8194649	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	4.52	CHEMBL2116	Homo sapiens	Inhibition	%	4.52
	8194792	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	4.03	CHEMBL2116	Homo sapiens	Inhibition	%	4.03
	8195149	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	3.88	CHEMBL2116	Homo sapiens	Inhibition	%	3.88
	8195313	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	3.01	CHEMBL2116	Homo sapiens	Inhibition	%	3.01
	8195537	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	10.82	CHEMBL2116	Homo sapiens	Inhibition	%	10.82
	8195676	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.09	CHEMBL2116	Homo sapiens	Inhibition	%	2.09
	8195998	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	4.16	CHEMBL2116	Homo sapiens	Inhibition	%	4.16
	8196115	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	-0.36	CHEMBL2116	Homo sapiens	Inhibition	%	-0.36
	8196339	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	2.91	CHEMBL2116	Homo sapiens	Inhibition	%	2.91
	8196489	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	0.59	CHEMBL2116	Homo sapiens	Inhibition	%	0.59
	8196841	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	3.12	CHEMBL2116	Homo sapiens	Inhibition	%	3.12
	8196982	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	6.66	CHEMBL2116	Homo sapiens	Inhibition	%	6.66
	8197206	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.66	CHEMBL2116	Homo sapiens	Inhibition	%	0.66
	8197343	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	3.94	CHEMBL2116	Homo sapiens	Inhibition	%	3.94
	8197618	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.48	CHEMBL2116	Homo sapiens	Inhibition	%	2.48
	8197982	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	3.59	CHEMBL2116	Homo sapiens	Inhibition	%	3.59
	8198139	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	4.5	CHEMBL2116	Homo sapiens	Inhibition	%	4.5
	8198501	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	2.6	CHEMBL2116	Homo sapiens	Inhibition	%	2.6
	8198631	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	5.2	CHEMBL2116	Homo sapiens	Inhibition	%	5.2
	8198986	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	5.78	CHEMBL2116	Homo sapiens	Inhibition	%	5.78
	8199134	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	4.92	CHEMBL2116	Homo sapiens	Inhibition	%	4.92
	8199358	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	4.85	CHEMBL2116	Homo sapiens	Inhibition	%	4.85
	8199492	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.38	CHEMBL2116	Homo sapiens	Inhibition	%	1.38
	8199879	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	2.92	CHEMBL2116	Homo sapiens	Inhibition	%	2.92
	8200017	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	4.26	CHEMBL2116	Homo sapiens	Inhibition	%	4.26
	8200345	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.86	CHEMBL2116	Homo sapiens	Inhibition	%	1.86
	8200684	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	2.66	CHEMBL2116	Homo sapiens	Inhibition	%	2.66
	8200834	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	3.36	CHEMBL2116	Homo sapiens	Inhibition	%	3.36
	8201058	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	-0.07	CHEMBL2116	Homo sapiens	Inhibition	%	-0.07
	8201188	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	5.5	CHEMBL2116	Homo sapiens	Inhibition	%	5.5
	8201547	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	2.32	CHEMBL2116	Homo sapiens	Inhibition	%	2.32
	8201680	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	3.22	CHEMBL2116	Homo sapiens	Inhibition	%	3.22
	8201959	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	3.2	CHEMBL2116	Homo sapiens	Inhibition	%	3.2
	8202323	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	3.28	CHEMBL2116	Homo sapiens	Inhibition	%	3.28
	8202490	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	5.23	CHEMBL2116	Homo sapiens	Inhibition	%	5.23
	8202839	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.61	CHEMBL2116	Homo sapiens	Inhibition	%	1.61
	8202969	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	3.83	CHEMBL2116	Homo sapiens	Inhibition	%	3.83
	8203193	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	5.48	CHEMBL2116	Homo sapiens	Inhibition	%	5.48
	8203324	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	3.67	CHEMBL2116	Homo sapiens	Inhibition	%	3.67
	8203694	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	3.24	CHEMBL2116	Homo sapiens	Inhibition	%	3.24
	8203828	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	2.35	CHEMBL2116	Homo sapiens	Inhibition	%	2.35
	8204052	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	0.83	CHEMBL2116	Homo sapiens	Inhibition	%	0.83
	8204218	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	4.01	CHEMBL2116	Homo sapiens	Inhibition	%	4.01
	8204355	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.74	CHEMBL2116	Homo sapiens	Inhibition	%	1.74
	8204579	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	6.05	CHEMBL2116	Homo sapiens	Inhibition	%	6.05
	8204684	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	2.26	CHEMBL2116	Homo sapiens	Inhibition	%	2.26
	8205023	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	20.24	CHEMBL2116	Homo sapiens	Inhibition	%	20.24
	8205396	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	7.62	CHEMBL2116	Homo sapiens	Inhibition	%	7.62
	8205532	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	2.19	CHEMBL2116	Homo sapiens	Inhibition	%	2.19
	8205895	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	1.0	CHEMBL2116	Homo sapiens	Inhibition	%	1.0
	8206027	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	1.05	CHEMBL2116	Homo sapiens	Inhibition	%	1.05
	8206251	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	3.33	CHEMBL2116	Homo sapiens	Inhibition	%	3.33
	8206303	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	3.63	CHEMBL2116	Homo sapiens	Inhibition	%	3.63
	8206527	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	3.74	CHEMBL2116	Homo sapiens	Inhibition	%	3.74
	8206670	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	1.63	CHEMBL2116	Homo sapiens	Inhibition	%	1.63
	8206850	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	3.05	CHEMBL2116	Homo sapiens	Inhibition	%	3.05
	8207074	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	5.42	CHEMBL2116	Homo sapiens	Inhibition	%	5.42
	8207200	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	3.05	CHEMBL2116	Homo sapiens	Inhibition	%	3.05
	8207554	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	4.36	CHEMBL2116	Homo sapiens	Inhibition	%	4.36
	8207686	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	5.34	CHEMBL2116	Homo sapiens	Inhibition	%	5.34
	8207910	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	-0.75	CHEMBL2116	Homo sapiens	Inhibition	%	-0.75
	8208055	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	2.36	CHEMBL2116	Homo sapiens	Inhibition	%	2.36
	8208411	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	3.44	CHEMBL2116	Homo sapiens	Inhibition	%	3.44
	8208577	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	2.46	CHEMBL2116	Homo sapiens	Inhibition	%	2.46
	8208934	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.84	CHEMBL2116	Homo sapiens	Inhibition	%	1.84
	8209039	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.79	CHEMBL2116	Homo sapiens	Inhibition	%	1.79
	8209263	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.37	CHEMBL2116	Homo sapiens	Inhibition	%	1.37
	8209379	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1	Outside typical range	CHEMBL181361	=	Inhibition	%	-14.22	CHEMBL2116	Homo sapiens	Inhibition	%	-14.22
	8209753	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	-0.68	CHEMBL2116	Homo sapiens	Inhibition	%	-0.68
	8209889	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	4.98	CHEMBL2116	Homo sapiens	Inhibition	%	4.98
	8210113	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	2.58	CHEMBL2116	Homo sapiens	Inhibition	%	2.58
	8210254	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	3.66	CHEMBL2116	Homo sapiens	Inhibition	%	3.66
	8210614	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	5.99	CHEMBL2116	Homo sapiens	Inhibition	%	5.99
	8210873	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	3.56	CHEMBL2116	Homo sapiens	Inhibition	%	3.56
	8211017	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	-0.41	CHEMBL2116	Homo sapiens	Inhibition	%	-0.41
	8211411	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	3.89	CHEMBL2116	Homo sapiens	Inhibition	%	3.89
	8211534	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	3.28	CHEMBL2116	Homo sapiens	Inhibition	%	3.28
	8211758	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	2.37	CHEMBL2116	Homo sapiens	Inhibition	%	2.37
	8211887	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	12.08	CHEMBL2116	Homo sapiens	Inhibition	%	12.08
	8212243	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	7.06	CHEMBL2116	Homo sapiens	Inhibition	%	7.06
	8212384	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	3.71	CHEMBL2116	Homo sapiens	Inhibition	%	3.71
	8212741	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	0.86	CHEMBL2116	Homo sapiens	Inhibition	%	0.86
	8212911	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	11.46	CHEMBL2116	Homo sapiens	Inhibition	%	11.46
	8213264	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	7.08	CHEMBL2116	Homo sapiens	Inhibition	%	7.08
	8213592	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	0.26	CHEMBL2116	Homo sapiens	Inhibition	%	0.26
	8213705	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	3.76	CHEMBL2116	Homo sapiens	Inhibition	%	3.76
	8213929	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	-0.6	CHEMBL2116	Homo sapiens	Inhibition	%	-0.6
	8214076	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	5.62	CHEMBL2116	Homo sapiens	Inhibition	%	5.62
	8214437	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	8.68	CHEMBL2116	Homo sapiens	Inhibition	%	8.68
	8214571	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	1.35	CHEMBL2116	Homo sapiens	Inhibition	%	1.35
	8214947	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	6.57	CHEMBL2116	Homo sapiens	Inhibition	%	6.57
	8215198	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	3.33	CHEMBL2116	Homo sapiens	Inhibition	%	3.33
	8215351	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	5.51	CHEMBL2116	Homo sapiens	Inhibition	%	5.51
	8215575	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	4.54	CHEMBL2116	Homo sapiens	Inhibition	%	4.54
	8215739	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	3.87	CHEMBL2116	Homo sapiens	Inhibition	%	3.87
	8216082	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	3.64	CHEMBL2116	Homo sapiens	Inhibition	%	3.64
	8216201	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	3.14	CHEMBL2116	Homo sapiens	Inhibition	%	3.14
	8216561	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	5.22	CHEMBL2116	Homo sapiens	Inhibition	%	5.22
	8216699	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	6.01	CHEMBL2116	Homo sapiens	Inhibition	%	6.01
	8216923	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	3.94	CHEMBL2116	Homo sapiens	Inhibition	%	3.94
	8217057	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	4.4	CHEMBL2116	Homo sapiens	Inhibition	%	4.4
	8217231	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	1.31	CHEMBL2116	Homo sapiens	Inhibition	%	1.31
	8217455	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	2.49	CHEMBL2116	Homo sapiens	Inhibition	%	2.49
	8217586	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	5.84	CHEMBL2116	Homo sapiens	Inhibition	%	5.84
	8217911	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.57	CHEMBL2116	Homo sapiens	Inhibition	%	-0.57
	8218250	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	2.75	CHEMBL2116	Homo sapiens	Inhibition	%	2.75
	8218377	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	2.3	CHEMBL2116	Homo sapiens	Inhibition	%	2.3
	8218744	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	1.55	CHEMBL2116	Homo sapiens	Inhibition	%	1.55
	8218875	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	5.29	CHEMBL2116	Homo sapiens	Inhibition	%	5.29
	8219099	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	0.79	CHEMBL2116	Homo sapiens	Inhibition	%	0.79
	8219259	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	4.37	CHEMBL2116	Homo sapiens	Inhibition	%	4.37
	8219509	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	4.51	CHEMBL2116	Homo sapiens	Inhibition	%	4.51
	8219894	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	5.94	CHEMBL2116	Homo sapiens	Inhibition	%	5.94
	8220063	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	5.57	CHEMBL2116	Homo sapiens	Inhibition	%	5.57
	8220416	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.48	CHEMBL2116	Homo sapiens	Inhibition	%	2.48
	8220530	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	3.78	CHEMBL2116	Homo sapiens	Inhibition	%	3.78
	8220754	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	5.35	CHEMBL2116	Homo sapiens	Inhibition	%	5.35
	8220892	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	14.33	CHEMBL2116	Homo sapiens	Inhibition	%	14.33
	8221252	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	5.85	CHEMBL2116	Homo sapiens	Inhibition	%	5.85
	8221385	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	0.48	CHEMBL2116	Homo sapiens	Inhibition	%	0.48
	8221774	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.97	CHEMBL2116	Homo sapiens	Inhibition	%	1.97
	8221905	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	31.17	CHEMBL2116	Homo sapiens	Inhibition	%	31.17
	8222129	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	1.22	CHEMBL2116	Homo sapiens	Inhibition	%	1.22
	8222227	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	-0.37	CHEMBL2116	Homo sapiens	Inhibition	%	-0.37
	8222585	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	1.03	CHEMBL2116	Homo sapiens	Inhibition	%	1.03
	8222703	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	14.51	CHEMBL2116	Homo sapiens	Inhibition	%	14.51
	8222927	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	-0.12	CHEMBL2116	Homo sapiens	Inhibition	%	-0.12
	8223071	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	7.89	CHEMBL2116	Homo sapiens	Inhibition	%	7.89
	8223424	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	4.55	CHEMBL2116	Homo sapiens	Inhibition	%	4.55
	8223585	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.65	CHEMBL2116	Homo sapiens	Inhibition	%	2.65
	8223835	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	4.21	CHEMBL2116	Homo sapiens	Inhibition	%	4.21
	8224059	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	3.5	CHEMBL2116	Homo sapiens	Inhibition	%	3.5
	8224221	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	6.89	CHEMBL2116	Homo sapiens	Inhibition	%	6.89
	8224391	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	5.29	CHEMBL2116	Homo sapiens	Inhibition	%	5.29
	8224615	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	3.84	CHEMBL2116	Homo sapiens	Inhibition	%	3.84
	8224750	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	4.32	CHEMBL2116	Homo sapiens	Inhibition	%	4.32
	8225088	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	16.28	CHEMBL2116	Homo sapiens	Inhibition	%	16.28
	8225222	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	5.11	CHEMBL2116	Homo sapiens	Inhibition	%	5.11
	8225584	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	3.38	CHEMBL2116	Homo sapiens	Inhibition	%	3.38
	8225719	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	2.95	CHEMBL2116	Homo sapiens	Inhibition	%	2.95
	8225943	CHEMBL1961944	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.66	CHEMBL2116	Homo sapiens	Inhibition	%	1.66
	8226101	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.34	CHEMBL2116	Homo sapiens	Inhibition	%	1.34
	8226450	CHEMBL1961945	GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	6.02	CHEMBL2116	Homo sapiens	Inhibition	%	6.02
	12047333	CHEMBL2157610	Inhibition of PRKAA2 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	3.1	CHEMBL2116	Homo sapiens	INH	%	3.1
	12173738	CHEMBL2212077	Inhibition of AMPK-alpha2 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	82.0	CHEMBL2116	Homo sapiens	Activity	%	82.0
	12183830	CHEMBL2214430	Inhibition of PRKAA2	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL2116	Homo sapiens	pIC50		5.0
	12673101	CHEMBL2346089	Inhibition of recombinant AMPK (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336379	=	Activity	%	22.0	CHEMBL2116	Homo sapiens	Activity	%	22.0
	12673102	CHEMBL2346089	Inhibition of recombinant AMPK (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336377	=	Activity	%	29.0	CHEMBL2116	Homo sapiens	Activity	%	29.0
	12726840	CHEMBL2353542	Ratio of compound activity to metformin activity for activation of AMPK in triple-negative human Hs575T cells	B	CCCc1ccccc1Nc1nc(N)nc(N(C)C)n1.Cl		CHEMBL2348411	=	Ratio		100.0	CHEMBL2116	Homo sapiens	Ratio		100.0
Active	12726843	CHEMBL2353545	Activation of AMPK in triple-negative human Hs575T cells at 0.2 mM after 24 hrs by immunoblot analysis	B	CCCc1ccccc1Nc1nc(N)nc(N(C)C)n1.Cl		CHEMBL2348411		Activity			CHEMBL2116	Homo sapiens	Activity		
Active	12726844	CHEMBL2353546	Activation of AMPK in triple-negative human Hs575T cells at 20 mM after 24 hrs by immunoblot analysis	B	CN(C)C(=N)N=C(N)N.Cl		CHEMBL1703		Activity			CHEMBL2116	Homo sapiens	Activity		
	12728904	CHEMBL2350238	Inhibition of AMPK (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	105.0	CHEMBL2116	Homo sapiens	Activity	%	105.0
	12730046	CHEMBL2353921	Inhibition of AMPK (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	107.0	CHEMBL2116	Homo sapiens	Activity	%	107.0
	12731183	CHEMBL2350238	Inhibition of AMPK (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	109.0	CHEMBL2116	Homo sapiens	Activity	%	109.0
	13324780	CHEMBL2390473	Activation of human AMPK alpha2 (1 to 398) expressed in African green monkey COS7 cells	B	Cc1cc(-c2ccc(/C=C3\S/C(=N\c4ccc(Cl)c(C(=O)O)c4)NC3=O)o2)c([N+](=O)[O-])cc1C		CHEMBL1242297	=	EC50	nM	12000.0	CHEMBL2116	Homo sapiens	EC50	uM	12.0
	13351024	CHEMBL2400677	Activation of human recombinant AMPK at 20 uM after 30 mins relative to control	B	Cc1cc(-c2ccc(/C=C3/S/C(=N\c4ccc(Cl)c(C(=O)O)c4)NC3=O)o2)c([N+](=O)[O-])cc1C		CHEMBL2398111	=	FC		2.04	CHEMBL2116	Homo sapiens	FC		2.04
	13351112	CHEMBL2400677	Activation of human recombinant AMPK at 20 uM after 30 mins relative to control	B	CCOc1ccc2nc(SCc3nc4ccccc4s3)sc2c1		CHEMBL2398110	=	FC		4.3	CHEMBL2116	Homo sapiens	FC		4.3
	13371355	CHEMBL2404108	Inhibition of AMPK (unknown origin) at 10 uM by Z'-LYTE kinase assay	B	c1ccc(-c2csc3ncnc(N4CCc5ccccc5C4)c23)cc1		CHEMBL1483261	=	Inhibition	%	3.37	CHEMBL2116	Homo sapiens	INH	%	3.37
	13439898	CHEMBL2428326	Competitive binding affinity to AMPKalpha2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	13445404	CHEMBL2428326	Competitive binding affinity to AMPKalpha2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	=	Inhibition	%	89.0	CHEMBL2116	Homo sapiens	INH	%	89.0
	13448463	CHEMBL2428326	Competitive binding affinity to AMPKalpha2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	13451718	CHEMBL2428326	Competitive binding affinity to AMPKalpha2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	=	Inhibition	%	74.0	CHEMBL2116	Homo sapiens	INH	%	74.0
	13476390	CHEMBL2438989	Inhibition of human wild type AMPKalpha2 at 1 uM by qPCR analysis relative to control	B	CCSCc1ccc2c(c1)c1c3c(c4c5cc(CSCC)ccc5n5c4c1n2[C@H]1C[C@](O)(C(=O)OC)[C@]5(C)O1)CNC3=O		CHEMBL290352	=	Inhibition	%	98.0	CHEMBL2116	Homo sapiens	INH	%	98.0
	13954573	CHEMBL3132496	Inhibition of human AMPKalpha2 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	46.0	CHEMBL2116	Homo sapiens	Activity	%	46.0
	13954779	CHEMBL3132496	Inhibition of human AMPKalpha2 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	42.0	CHEMBL2116	Homo sapiens	Activity	%	42.0
	13954791	CHEMBL3132496	Inhibition of human AMPKalpha2 assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	28.0	CHEMBL2116	Homo sapiens	Activity	%	28.0
	14979196	CHEMBL3379069	Inhibition of AMPKalpha2 (unknown origin) at 1 uM by Millipore kinase analysis	B	COc1cc(-c2cn[nH]c2)ccc1C(=O)Nc1ccc2c(c1)CCNCC2	Outside typical range	CHEMBL3355059	=	Inhibition	%	-12.0	CHEMBL2116	Homo sapiens	INH	%	-12.0
	15037148	CHEMBL3368325	Inhibition of AMPKalpha 2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1OC		CHEMBL3102948	=	Inhibition	%	81.0	CHEMBL2116	Homo sapiens	INH	%	81.0
	15037149	CHEMBL3368325	Inhibition of AMPKalpha 2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1cc(-c2c[nH]c3ncc(-c4cccc(N)c4)cc23)cc(OC)c1OC		CHEMBL3319457	=	Inhibition	%	77.0	CHEMBL2116	Homo sapiens	INH	%	77.0
	15037150	CHEMBL3368325	Inhibition of AMPKalpha 2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4ccc(C(=O)N5CCOCC5)c(N)c4)cc23)cc1OC		CHEMBL3319467	=	Inhibition	%	82.0	CHEMBL2116	Homo sapiens	INH	%	82.0
	15037151	CHEMBL3368325	Inhibition of AMPKalpha 2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2c[nH]c3ncc(-c4cc(OC)c(OC)c(OC)c4)cc23)cc1OC		CHEMBL3319468	=	Inhibition	%	86.0	CHEMBL2116	Homo sapiens	INH	%	86.0
	15037152	CHEMBL3368325	Inhibition of AMPKalpha 2 (unknown origin) at 1 uM by KINOMEscanning assay relative to control	B	COc1ccc(-c2cnc3[nH]cc(-c4ccc(OC)c(OC)c4)c3c2)cc1N		CHEMBL3319470	=	Inhibition	%	87.0	CHEMBL2116	Homo sapiens	INH	%	87.0
	15122487	CHEMBL3367679	Inhibition of human AMPKalpha2 assessed as residual activity at 10 uM by KinaseProfiler assay	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3ccc(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331445	=	Activity	%	65.0	CHEMBL2116	Homo sapiens	Activity	%	65.0
	15126950	CHEMBL3367679	Inhibition of human AMPKalpha2 assessed as residual activity at 10 uM by KinaseProfiler assay	B	CCOC(=O)C1=C(C)N=c2s/c(=C\c3cc(O)c(O)c(O)c3)c(=O)n2C1c1ccc(Cl)cc1		CHEMBL3331446	=	Activity	%	48.0	CHEMBL2116	Homo sapiens	Activity	%	48.0
	15126982	CHEMBL3367679	Inhibition of human AMPKalpha2 assessed as residual activity at 10 uM by KinaseProfiler assay	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	Activity	%	83.0	CHEMBL2116	Homo sapiens	Activity	%	83.0
	15258390	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Thermal melting change	degrees C	-0.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.6
	15258450	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15258510	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Thermal melting change	degrees C	5.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	5.8
	15258570	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Thermal melting change	degrees C	0.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.6
	15258630	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Thermal melting change	degrees C	-0.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.9
	15258690	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Thermal melting change	degrees C	0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.4
	15258750	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C(O)Cc1ccc(O)c([N+](=O)[O-])c1		CHEMBL501822	=	Thermal melting change	degrees C	0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.1
	15258810	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL319467	=	Thermal melting change	degrees C	1.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.9
	15258870	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Thermal melting change	degrees C	3.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	3.6
	15258930	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL1642	=	Thermal melting change	degrees C	2.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.6
	15258990	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Thermal melting change	degrees C	6.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	6.0
	15259050	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Thermal melting change	degrees C	1.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.0
	15259110	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL216543	=	Thermal melting change	degrees C	6.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	6.6
	15259170	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Thermal melting change	degrees C	10.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	10.1
	15259230	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cn1cc(/C=C2/C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL3430785	=	Thermal melting change	degrees C	8.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	8.3
	15259290	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B			CHEMBL3430786	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15259350	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCOc1ccc(/C=C2/SC(=O)N(CCN)C2=O)cc1		CHEMBL262615	=	Thermal melting change	degrees C	0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.1
	15259410	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=c1c(-c2ccc(F)cc2)c(-c2ccncc2)[nH]n1-c1ccc(Cl)cc1		CHEMBL408678	=	Thermal melting change	degrees C	0.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.2
	15259470	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Thermal melting change	degrees C	-0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.4
	15259530	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Thermal melting change	degrees C	0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.4
	15259590	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2[C@H]2CC[C@H](O)CC2)n1		CHEMBL97162	=	Thermal melting change	degrees C	0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.7
	15259650	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Thermal melting change	degrees C	1.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.3
	15259710	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Thermal melting change	degrees C	7.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	7.4
	15259770	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl		CHEMBL406381	=	Thermal melting change	degrees C	2.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.1
	15259830	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Thermal melting change	degrees C	0.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.8
	15259890	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Thermal melting change	degrees C	0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.1
	15259950	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cl.NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL558969	=	Thermal melting change	degrees C	0.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.3
	15260010	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)c(C)c1C(=O)N1CCN(C)CC1		CHEMBL261641	=	Thermal melting change	degrees C	4.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	4.0
	15260070	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Thermal melting change	degrees C	0.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.0
	15260130	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Thermal melting change	degrees C	-0.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.3
	15260190	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B			CHEMBL3430787	=	Thermal melting change	degrees C	2.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.4
	15260250	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Thermal melting change	degrees C	-3.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-3.7
	15260310	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN(c1cccnc1)c1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cn1		CHEMBL261238	=	Thermal melting change	degrees C	4.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	4.8
	15260370	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Thermal melting change	degrees C	1.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.0
	15260430	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Thermal melting change	degrees C	0.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.0
	15260490	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1nc(N)sc1-c1ccnc(Nc2cccc([N+](=O)[O-])c2)n1		CHEMBL298445	=	Thermal melting change	degrees C	3.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	3.0
	15260550	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Thermal melting change	degrees C	1.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.5
	15260610	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B			CHEMBL3430788	=	Thermal melting change	degrees C	0.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.8
	15260670	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Thermal melting change	degrees C	0.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.3
	15260730	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Thermal melting change	degrees C	-0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.4
	15260790	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN1CCc2[nH]c(=S)c(C#N)c(-c3cccs3)c2C1		CHEMBL261211	=	Thermal melting change	degrees C	0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.4
	15260850	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(O)c1c(F)cccc1F		CHEMBL259605	=	Thermal melting change	degrees C	2.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.2
	15260910	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Thermal melting change	degrees C	0.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.2
	15260970	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15261030	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1		CHEMBL258940	=	Thermal melting change	degrees C	0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.1
	15261090	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	=	Thermal melting change	degrees C	-0.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.3
	15261173	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Thermal melting change	degrees C	-0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.4
	15261233	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	Thermal melting change	degrees C	0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.4
	15261293	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Nc1cc2ncnc(Nc3cccc(Br)c3)c2cc1N		CHEMBL328216	=	Thermal melting change	degrees C	-0.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.9
	15261353	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Thermal melting change	degrees C	0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.1
	15261408	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	NC1=N/C(=C2/CCNC(=O)c3[nH]ccc32)C(=O)N1		CHEMBL255465	=	Thermal melting change	degrees C	-0.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.5
	15261468	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc(OC)c(OC)c2)ccc1O		CHEMBL435734	=	Thermal melting change	degrees C	-0.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.9
	15261528	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1C=C2C(=Nc3c2c2c(c4c3=NC3=C4CCC=C3)C=NC=2)CC1		CHEMBL408953	=	Thermal melting change	degrees C	-0.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.2
	15261588	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC.[Cl-]		CHEMBL258893	=	Thermal melting change	degrees C	-1.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-1.3
	15261661	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC		CHEMBL29197	=	Thermal melting change	degrees C	-0.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.5
	15261721	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	C[S+]([O-])c1ccc(CSc2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL111456	=	Thermal melting change	degrees C	-0.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.3
	15261781	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28	=	Thermal melting change	degrees C	1.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.5
	15261841	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12		CHEMBL44	=	Thermal melting change	degrees C	1.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.6
	15261897	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Thermal melting change	degrees C	-0.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.9
	15261957	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)c1cc(/C=C(\C#N)C(=O)NCCCc2ccccc2)cc(C(C)C)c1O		CHEMBL261508	=	Thermal melting change	degrees C	-0.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.8
	15262017	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Thermal melting change	degrees C	-1.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-1.0
	15262077	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B			CHEMBL3430782	=	Thermal melting change	degrees C	1.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.9
	15262137	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Thermal melting change	degrees C	7.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	7.0
	15262150	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc21		CHEMBL264406	=	Thermal melting change	degrees C	0.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.0
	15262210	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	=	Thermal melting change	degrees C	0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.7
	15262270	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Nc1ncnc2c1c(I)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O		CHEMBL99203	=	Thermal melting change	degrees C	1.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.0
	15262330	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C(O)c1cc(NCc2cc(O)ccc2O)ccc1O		CHEMBL319620	=	Thermal melting change	degrees C	-0.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.8
	15262390	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	OC[C@H]1O[C@@H](n2cnc3cc(Cl)c(Cl)cc32)[C@H](O)[C@@H]1O		CHEMBL375530	=	Thermal melting change	degrees C	-0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.7
	15262450	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C(O)c1cc(N(Cc2ccccc2O)Cc2cc(O)ccc2O)ccc1O		CHEMBL103552	=	Thermal melting change	degrees C	-1.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-1.1
	15262510	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Nc2ccc(I)cc2/C1=C\c1cc(Br)c(O)c(Br)c1		CHEMBL264949	=	Thermal melting change	degrees C	1.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.0
	15262570	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Thermal melting change	degrees C	-0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.7
	15262630	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN(C)c1ncnc2nc[nH]c12		CHEMBL407391	=	Thermal melting change	degrees C	-0.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.6
	15262690	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1ccc2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL405992	=	Thermal melting change	degrees C	-0.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.9
	15262750	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=c1ccc2ccc(O)c(O)c2o1		CHEMBL244948	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15262810	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cc(O)c2c(c1)oc(=O)c1c3cc(O)c(O)cc3oc21		CHEMBL97453	=	Thermal melting change	degrees C	-0.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.8
	15262870	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Thermal melting change	degrees C	2.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.2
	15262930	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Thermal melting change	degrees C	3.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	3.9
	15262990	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Thermal melting change	degrees C	1.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.1
	15263050	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Thermal melting change	degrees C	0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.7
	15263110	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	N#CC(C#N)=Cc1ccc(O)c(O)c1		CHEMBL76904	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15263170	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Thermal melting change	degrees C	-0.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.2
	15263230	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1ccccc1		CHEMBL56731	=	Thermal melting change	degrees C	-0.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.3
	15263290	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCOc1cc(/C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O		CHEMBL485070	=	Thermal melting change	degrees C	0.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.0
	15263350	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br		CHEMBL228043	=	Thermal melting change	degrees C	0.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.6
	15263386	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Thermal melting change	degrees C	2.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.4
	15263446	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Thermal melting change	degrees C	0.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.5
	15263501	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1c2ccccc2-c2n[nH]c3cccc1c23		CHEMBL7064	=	Thermal melting change	degrees C	2.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.1
	15263561	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B			CHEMBL3430783	=	Thermal melting change	degrees C	1.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.9
	15263621	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccccc2)c2ccc(F)cc2)CC1		CHEMBL259388	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15263681	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12		CHEMBL123	=	Thermal melting change	degrees C	1.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.8
	15263755	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12		CHEMBL406821	=	Thermal melting change	degrees C	1.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.7
	15263815	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Thermal melting change	degrees C	0.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.5
	15263875	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN(C)c1ccc(CC2C(=O)Nc3ccccc32)cc1		CHEMBL1373282	=	Thermal melting change	degrees C	0.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.3
	15263935	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Nc2ccccc2/C1=C/c1cc2c([nH]1)CCC(Br)C2		CHEMBL408565	=	Thermal melting change	degrees C	1.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.3
	15263989	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCOC(=O)c1cnc2oc3ccc(O)cc3c2c1-c1ccccc1		CHEMBL132904	=	Thermal melting change	degrees C	0.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.0
	15264049	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21.[Cl-]		CHEMBL258765	=	Thermal melting change	degrees C	0.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.0
	15264109	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O		CHEMBL278315	=	Thermal melting change	degrees C	0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.4
	15264169	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Thermal melting change	degrees C	0.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.6
	15264242	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Nc2ccccc2/C1=C/c1cnc[nH]1		CHEMBL261692	=	Thermal melting change	degrees C	3.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	3.3
	15264302	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=S(=O)(c1cccc2c(Cl)cccc12)N1CCCNCC1		CHEMBL429298	=	Thermal melting change	degrees C	-0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.4
	15264362	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O		CHEMBL116438	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15264422	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	NC1=NC(=O)/C(=C2\CCNC(=O)c3[nH]c(Br)cc32)N1		CHEMBL361708	=	Thermal melting change	degrees C	1.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.0
	15264478	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Thermal melting change	degrees C	4.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	4.5
	15264538	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COC(=O)[C@]1(O)C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL416056	=	Thermal melting change	degrees C	7.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	7.6
	15264598	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Thermal melting change	degrees C	-1.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-1.0
	15264658	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cl.NCCNS(=O)(=O)c1cccc2c(Cl)cccc12		CHEMBL1255867	=	Thermal melting change	degrees C	-0.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.2
	15264730	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1cc(C=C2C(=O)C=CC2=O)cc(C)c1O		CHEMBL437612	=	Thermal melting change	degrees C	-2.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-2.2
	15264790	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)(C)c1cc(C=C2C(=O)C=CC2=O)cc(C(C)(C)C)c1O		CHEMBL258726	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15264850	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Thermal melting change	degrees C	6.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	6.4
	15264910	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)N(CCO)c1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL126254	=	Thermal melting change	degrees C	0.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.2
	15264966	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	N=C(N)NCCNS(=O)(=O)c1cccc2cnccc12		CHEMBL143054	=	Thermal melting change	degrees C	0.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.5
	15265026	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CNC(=O)c1cc(Oc2ccc(Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL3430784	=	Thermal melting change	degrees C	0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.1
	15265086	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15265146	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CCn1cnc2c(N)nc(N(c3cccc(Cl)c3)[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL411901	=	Thermal melting change	degrees C	1.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.4
	15265206	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Thermal melting change	degrees C	0.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.9
	15265219	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Thermal melting change	degrees C	0.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.3
	15265279	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc21		CHEMBL280074	=	Thermal melting change	degrees C	0.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.2
	15265339	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(C)n1cnc2c(NCc3ccccc3O)nc(NCCCO)nc21		CHEMBL419931	=	Thermal melting change	degrees C	0.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.2
	15265399	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Thermal melting change	degrees C	0.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.6
	15265459	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Thermal melting change	degrees C	0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.4
	15265515	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cc1ccc(NC(=O)c2cccc(N(C)C)c2)cc1NC(=O)c1ccc(O)cc1		CHEMBL186526	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15265575	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15265635	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	C[C@@H]1C[C@H]2O[C@@H]2/C=C\C=C\C(=O)Cc2c(Cl)c(O)cc(O)c2C(=O)O1		CHEMBL414883	=	Thermal melting change	degrees C	-0.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.3
	15265695	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Thermal melting change	degrees C	6.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	6.7
	15265767	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	Thermal melting change	degrees C	0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.4
	15265827	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C(O)/C=C/c1cc(CO)ccc1CO		CHEMBL407534	=	Thermal melting change	degrees C	0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.7
	15265887	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Thermal melting change	degrees C	-0.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.5
	15265947	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1CC(=O)c2[nH]c3c4[nH]c5c(c4c4cn(Br)cc4c3c2C1)CCC=C5		CHEMBL264685	=	Thermal melting change	degrees C	1.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.3
	15266004	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Oc1cc(O)cc(/C=C/c2ccc(O)c(O)c2)c1		CHEMBL69863	=	Thermal melting change	degrees C	0.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.2
	15266064	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	N#C/C(=C(/N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL261237	=	Thermal melting change	degrees C	-0.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.8
	15266124	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Nc2ccc(I)cc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL411645	=	Thermal melting change	degrees C	6.8	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	6.8
	15266184	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Nc2ccc(S(=O)(=O)O)cc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL440411	=	Thermal melting change	degrees C	5.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	5.5
	15266256	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Thermal melting change	degrees C	0.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.6
	15266316	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Thermal melting change	degrees C	-0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.7
	15266376	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1Nc2ccccc2/C1=C\c1ccc[nH]1		CHEMBL101797	=	Thermal melting change	degrees C	3.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	3.2
	15266436	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12		CHEMBL50	=	Thermal melting change	degrees C	2.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.3
	15266491	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(=O)O/N=C1C(=C2/C(=O)Nc3cc(Br)ccc32)/Nc2ccccc2/1		CHEMBL430226	=	Thermal melting change	degrees C	2.0	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.0
	15266551	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Thermal melting change	degrees C	2.6	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.6
	15266611	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CC(=O)O.Cn1cc(C2=C(c3cn(CCCN)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL3430781	=	Thermal melting change	degrees C	1.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.4
	15266671	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Thermal melting change	degrees C	1.2	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	1.2
	15266744	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15266804	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Thermal melting change	degrees C	4.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	4.1
	15266864	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Thermal melting change	degrees C	-3.3	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-3.3
	15266924	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Thermal melting change	degrees C	-0.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.1
	15266979	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CS(=O)(=O)O.Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL1591531	=	Thermal melting change	degrees C	2.1	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	2.1
	15267039	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Cl.Cn1cc(C2=C(c3ccc4cc5n(c4c3)CCC(CN)C5)C(=O)NC2=O)c2ccccc21		CHEMBL541401	=	Thermal melting change	degrees C	-0.4	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.4
	15267099	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN(C)CC1CCn2c(c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc32)C1		CHEMBL372585	=	Thermal melting change	degrees C	-0.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.5
	15267159	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	CN[C@@H]1CC2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL162	=	Thermal melting change	degrees C	16.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	16.7
	15267232	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Thermal melting change	degrees C	0.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	0.5
	15267292	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	COc1cc2ncnc(Nc3cccc(O)c3)c2cc1OC		CHEMBL127907	=	Thermal melting change	degrees C	-0.5	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.5
	15267352	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Thermal melting change	degrees C	-0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.7
	15267412	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Thermal melting change	degrees C	-0.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.9
	15267467	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	O=c1sn(Cc2ccccc2)c(=S)n1Cc1ccccc1		CHEMBL24338	=	Thermal melting change	degrees C	-0.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.9
	15267527	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	C=CNC#N		CHEMBL259526	=	Thermal melting change	degrees C	-0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.7
	15267587	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	N#CC(=C(/N)Sc1ccccc1N)/C(C#N)=C(/N)Sc1ccccc1N		CHEMBL100473	=	Thermal melting change	degrees C	-0.9	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.9
	15267647	CHEMBL3430789	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Thermal melting change	degrees C	-0.7	CHEMBL2116	Homo sapiens	Thermal melting change	degrees C	-0.7
	15728394	CHEMBL3624235	Inhibition of AMPK-alpha2 (unknown origin) at 10 uM	B	COc1ccc(-c2cnccc2-c2cnc(NC(=O)C(C)C)s2)c(C(F)(F)F)c1		CHEMBL3623443	>	Inhibition	%	90.0	CHEMBL2116	Homo sapiens	INH	%	90.0
	16451591	CHEMBL3761172	Inhibition of PRKAA2 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	10.9	CHEMBL2116	Homo sapiens	INH	%	10.9
	16495201	CHEMBL3777529	Inhibition of N-terminal His6-tagged recombinant human PRKAA2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	4.0	CHEMBL2116	Homo sapiens	Activity	%	4.0
	16496120	CHEMBL3777529	Inhibition of N-terminal His6-tagged recombinant human PRKAA2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	4.0	CHEMBL2116	Homo sapiens	Activity	%	4.0
	16508910	CHEMBL3777529	Inhibition of N-terminal His6-tagged recombinant human PRKAA2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	17.0	CHEMBL2116	Homo sapiens	Activity	%	17.0
	16619693	CHEMBL3820360	Inhibition of recombinant human PRKAA2 at 1 uM relative to control	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Inhibition	%	75.0	CHEMBL2116	Homo sapiens	INH	%	75.0
	16749990	CHEMBL3859881	Activation of human recombinant AMPK alpha2 expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL using SAMS peptide after 10 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(-c2ccc(/C=C3\S/C(=N\c4ccc(Cl)c(C(=O)O)c4)NC3=O)o2)c([N+](=O)[O-])cc1C		CHEMBL1242297	=	EC50	nM	12000.0	CHEMBL2116	Homo sapiens	EC50	uM	12.0
425911	17787805	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccc4[nH]c(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)nc4c3)CC2)cn1		CHEMBL3968294	=	EC50	nM	24.0	CHEMBL2116	Homo sapiens	EC50	nM	24.0
425912	17787806	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1cnc(CN2CCC(c3ccc4[nH]c(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)nc4c3)CC2)cn1		CHEMBL3950327	=	EC50	nM	8.3	CHEMBL2116	Homo sapiens	EC50	nM	8.3
425913	17787807	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1cnc(CN2CCC(c3ccc4[nH]c(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)nc4c3)CC2)cn1		CHEMBL3950327	=	EC50	nM	13.0	CHEMBL2116	Homo sapiens	EC50	nM	13.0
425914	17787808	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccc4nc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)[nH]c4c3)CC2)cc1		CHEMBL3892677	=	EC50	nM	34.0	CHEMBL2116	Homo sapiens	EC50	nM	34.0
425915	17787809	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccc4nc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)n(C)c4c3)CC2)cn1		CHEMBL3955631	=	EC50	nM	3.0	CHEMBL2116	Homo sapiens	EC50	nM	3.0
425916	17787810	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccc4c(c3)nc(C(=O)N3CCN(Cc5ccc(C(F)(F)F)cc5)CC3)n4C)CC2)cn1		CHEMBL3895466	=	EC50	nM	10.0	CHEMBL2116	Homo sapiens	EC50	nM	10.0
425917	17787811	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccc4nc(C(=O)N5CCN(Cc6ccc(C#N)cc6)CC5)[nH]c4c3)CC2)cn1		CHEMBL3966762	=	EC50	nM	19.0	CHEMBL2116	Homo sapiens	EC50	nM	19.0
425918	17787812	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccc4nc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)cn4c3)CC2)cn1		CHEMBL3904401	=	EC50	nM	3.6	CHEMBL2116	Homo sapiens	EC50	nM	3.6
425919	17787813	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccn4cc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)nc4c3)CC2)cn1		CHEMBL3929875	=	EC50	nM	5.1	CHEMBL2116	Homo sapiens	EC50	nM	5.1
425920	17787814	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccc4nc(C(=O)N5CCN(Cc6ccc7c(c6)OC(F)(F)O7)CC5)[nH]c4c3)CC2)cn1		CHEMBL3916942	=	EC50	nM	10.0	CHEMBL2116	Homo sapiens	EC50	nM	10.0
425921	17787815	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccc4nc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6F)CC5)[nH]c4c3)CC2)cn1		CHEMBL3986674	=	EC50	nM	13.0	CHEMBL2116	Homo sapiens	EC50	nM	13.0
425922	17787816	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3cc4cc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)n(C)c4cn3)CC2)cn1		CHEMBL3946485	=	EC50	nM	5.2	CHEMBL2116	Homo sapiens	EC50	nM	5.2
425923	17787817	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(c3ccn4nc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)cc4c3)CC2)cn1		CHEMBL3978948	=	EC50	nM	6.5	CHEMBL2116	Homo sapiens	EC50	nM	6.5
425924	17787818	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1cnc(CN2CCC(c3ccn4nc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)cc4c3)CC2)cn1		CHEMBL3941150	=	EC50	nM	14.0	CHEMBL2116	Homo sapiens	EC50	nM	14.0
425925	17787819	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1ccc(CN2CCC(n3cc4cc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)ccc4n3)CC2)cn1		CHEMBL3970694	=	EC50	nM	1.8	CHEMBL2116	Homo sapiens	EC50	nM	1.8
425926	17787820	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	CCOc1cnc(CN2CCC(n3cc4cc(C(=O)N5CCN(Cc6ccc(C(F)(F)F)cc6)CC5)ccc4n3)CC2)cn1		CHEMBL3969654	=	EC50	nM	0.86	CHEMBL2116	Homo sapiens	EC50	nM	0.86
425927	17787821	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	CCOc1cnc(CN2CCC(c3ccc4c(c3)cc(C(=O)N3CCN(Cc5ccc(C#N)cc5)CC3)n4C)CC2)cn1		CHEMBL3895006	=	EC50	nM	2.8	CHEMBL2116	Homo sapiens	EC50	nM	2.8
425928	17787822	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	CCOc1cnc(CN2CCC(c3ccc4cc(C(=O)N5CCN(Cc6ccc(C#N)cc6)CC5)n(C)c4c3)CC2)cn1		CHEMBL3955171	=	EC50	nM	1.8	CHEMBL2116	Homo sapiens	EC50	nM	1.8
425929	17787823	CHEMBL3888975	Activation Assay: In order to make MDA-MB-453 cell become 15000 cells per well, each 36 l was seeded in Leibovitz's L-15 medium including 10% fetal bovine serum (manufactured by Life Technologies Corp.) in a 384 well plate, followed by culturing at 37 C. overnight in the absence of CO2. The following day, the test compound and DMSO which is a solvent for the test compound as a negative control were diluted with a fresh medium so as to become 10-fold concentration of the final concentration, and the resultant product was added by 4 l to each well (the test compound had 10 steps in a final concentration from 10000 nM to 0.3 nM, a final concentration of DMSO was 0.1%), followed by culturing at 37 C. for 2 hours in the absence of CO2. After the incubation, 20 l of a 40% glyoxal solution (Nacalai Tesque) was added to each well, and then cells were fixed by leaving to stand at room temperature for 30 minutes. Thereafter, the supernatant was removed by centrifuging the plate, and then 0.1% Triton X-100-containing Phosphate-Buffered Saline (PBS) was added to each well by 20 followed by incubating at room temperature for 10 minutes. The 0.1% Triton X-100-containing PBS was removed by centrifuging for 8 seconds at 800 rpm (all solution removal operation by centrifuge described below were carried out under the same conditions), and then a blocking solution (ODYSSEY Blocking Buffer; manufactured by LiCOR Biosciences) was added to each well by 20 l, followed by leaving to stand at room temperature for 1 hour. The blocking solution was removed by centrifuging, with the exception of the blocking solution by centrifugation, and then a blocking solution which was diluted such that the amount of phosphorylation antibody (manufactured by Cell Signaling Technology, Inc) of ACC Ser79 as a primary antibody is 1/500 was added to each well by 10 followed by leaving to stand at 4 C. overnight. The following day, the reaction liquid was removed by centrifuging the plate, and then 0.05% Tween-20-containing Tris-Buffered Saline (TBS) (manufacture by Thermo Scientific Inc.; used in 1 in which 20TBS Tween-20 was diluted with ion-exchange water) was added to each well by 25 followed by washing each well by centrifugal removal. The washing of each well was repeated for a total of 3 times. After washing, a blocking solution which was diluted such that the amount of IRDye 800CW Goat anti-Rabbit IgG (manufactured by LiCoR Biosciences) as a secondary antibody is 1/1000 was added to each well by 10 l, followed by leaving to stand at room temperature for 1 hour. After the secondary antibody reaction, the reaction liquid was removed by centrifuging the plate, and then each well was washed three times with 0.05% Tween-20-containing TBS in the same manner as after the primary antibody reaction. After the washing solution was removed, without change, the plate was air-dried at room temperature for 3 hours or longer and signals were measured by Aerius (manufactured by LiCoR Biosciences).	B	COc1cnc(CN2CCC(c3ccc4c(c3)cc(C(=O)N3CCN(Cc5ccc(C#N)cc5)CC3)n4C)CC2)cn1		CHEMBL3983813	=	EC50	nM	3.3	CHEMBL2116	Homo sapiens	EC50	nM	3.3
	18114481	CHEMBL4025013	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	92.0	CHEMBL2116	Homo sapiens	Activity	%	92.0
	18153136	CHEMBL4034257	Inhibition of AMPKa2 Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	12.6	CHEMBL2116	Homo sapiens	INH	%	12.6
	18153350	CHEMBL4034258	Inhibition of AMPKa2 ATP binding site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	7.9	CHEMBL2116	Homo sapiens	INH	%	7.9
	18153351	CHEMBL4034255	Inhibition of AMPKa2 Lysine 1 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	6.0	CHEMBL2116	Homo sapiens	INH	%	6.0
	18203403	CHEMBL4043824	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	89.0	CHEMBL2116	Homo sapiens	Activity	%	89.0
	18211597	CHEMBL4045637	Inhibition of AMPKa2 labeling at conserved Lys2 (DLKPENVLLDAHMNAK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	17.5	CHEMBL2116	Homo sapiens	INH	%	17.5
	18211621	CHEMBL4045635	Inhibition of AMPKa2 labeling at conserved Lys1 (VAVKILNR) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	17.3	CHEMBL2116	Homo sapiens	INH	%	17.3
	18211782	CHEMBL4045878	Inhibition of AMPKa2 labeling at conserved Lys1 (VAVKILNR) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	7.7	CHEMBL2116	Homo sapiens	INH	%	7.7
	18211784	CHEMBL4045880	Inhibition of AMPKa2 labeling at conserved Lys2 (DLKPENVLLDAHMNAK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	14.0	CHEMBL2116	Homo sapiens	INH	%	14.0
	18253277	CHEMBL4054922	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	38.0	CHEMBL2116	Homo sapiens	Activity	%	38.0
	18253278	CHEMBL4054922	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	74.0	CHEMBL2116	Homo sapiens	Activity	%	74.0
	18274743	CHEMBL4118293	Inhibition of AMPKa2 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPENVLLDAHMNAK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl		CHEMBL3883384	=	Inhibition	%	76.0	CHEMBL2116	Homo sapiens	INH	%	76.0
	18274744	CHEMBL4118293	Inhibition of AMPKa2 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPENVLLDAHMNAK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl		CHEMBL3884839	=	Inhibition	%	0.2	CHEMBL2116	Homo sapiens	INH	%	0.2
	18274745	CHEMBL4118293	Inhibition of AMPKa2 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPENVLLDAHMNAK probe by mass-spectrometric analysis relative to control	B	COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O		CHEMBL1077979	=	Inhibition	%	33.6	CHEMBL2116	Homo sapiens	INH	%	33.6
	18440079	CHEMBL4156903	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	83.0	CHEMBL2116	Homo sapiens	Activity	%	83.0
	18484519	CHEMBL4185682	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	100.0	CHEMBL2116	Homo sapiens	Activity	%	100.0
	18485102	CHEMBL4185682	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	88.0	CHEMBL2116	Homo sapiens	Activity	%	88.0
	18507901	CHEMBL4190861	Inhibition of recombinant full-length human AMPKalpha2 at 1 uM using AMARAASAAALARRR as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	-9.0	CHEMBL2116	Homo sapiens	INH	%	-9.0
	18655638	CHEMBL4230582	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL2116	Homo sapiens	Activity	%	100.0
	18751732	CHEMBL4264171	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	100.0	CHEMBL2116	Homo sapiens	Activity	%	100.0
	18761501	CHEMBL4266522	Inhibition of human AMPKa2 at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1		CHEMBL4279192	=	Inhibition	%	81.0	CHEMBL2116	Homo sapiens	INH	%	81.0
	18761741	CHEMBL4266522	Inhibition of human AMPKa2 at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1		CHEMBL4278882	=	Inhibition	%	14.0	CHEMBL2116	Homo sapiens	INH	%	14.0
	18761904	CHEMBL4266522	Inhibition of human AMPKa2 at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1		CHEMBL4290222	=	Inhibition	%	-6.0	CHEMBL2116	Homo sapiens	INH	%	-6.0
	18857842	CHEMBL4307688	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	89.0	CHEMBL2116	Homo sapiens	Activity	%	89.0
	18892560	CHEMBL4314709	Inhibition of recombinant full-length human AMPKalpha2 assessed as residual activity at 10 uM using AMARAASAAALARRR as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	117.0	CHEMBL2116	Homo sapiens	Activity	%	117.0
	18919485	CHEMBL4322841	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged PRKAA2 (unknown origin) (10 to 552 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	45.0	CHEMBL2116	Homo sapiens	Kd	nM	45.0
	18919673	CHEMBL4322841	Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged PRKAA2 (unknown origin) (10 to 552 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	46.0	CHEMBL2116	Homo sapiens	Kd	nM	46.0
	18958683	CHEMBL4333280	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	100.0	CHEMBL2116	Homo sapiens	Activity	%	100.0
	18964066	CHEMBL4334967	Inhibition of recombinant full length human AMPKalpha2 assessed as residual activity at 1 uM using AMARAASAAALAR as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	44.0	CHEMBL2116	Homo sapiens	Activity	%	44.0
	18964067	CHEMBL4334967	Inhibition of recombinant full length human AMPKalpha2 assessed as residual activity at 1 uM using AMARAASAAALAR as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	33.0	CHEMBL2116	Homo sapiens	Activity	%	33.0
	18971784	CHEMBL4336794	Inhibition of recombinant full length human AMPKalpha2 assessed as residual activity at 10 uM using AMARAASAAALAR as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	35.0	CHEMBL2116	Homo sapiens	Activity	%	35.0
Not Active	19039898	CHEMBL4351733	Inhibition of recombinant full-length human AMPKalpha2 at 10 uM using AMARAASAAALARRR as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL2116	Homo sapiens	INH		
	19059459	CHEMBL4357760	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL2116	Homo sapiens	Activity	%	100.0
	19072941	CHEMBL4362117	Effect on AMPK alpha2 at T172 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	FC		0.99	CHEMBL2116	Homo sapiens	FC		0.99
	19072980	CHEMBL4362155	Effect on AMPK alpha2 at T172 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	FC		1.11	CHEMBL2116	Homo sapiens	FC		1.11
	19073019	CHEMBL4362117	Effect on AMPK alpha2 at T172 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	log2FC		-0.02	CHEMBL2116	Homo sapiens	log2FC		-0.02
	19073058	CHEMBL4362155	Effect on AMPK alpha2 at T172 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	log2FC		0.15	CHEMBL2116	Homo sapiens	log2FC		0.15
	19073120	CHEMBL4362117	Effect on AMPK alpha2 at T172 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	FC		0.83	CHEMBL2116	Homo sapiens	FC		0.83
	19073159	CHEMBL4362155	Effect on AMPK alpha2 at T172 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	FC		0.97	CHEMBL2116	Homo sapiens	FC		0.97
	19073198	CHEMBL4362117	Effect on AMPK alpha2 at T172 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	log2FC		-0.27	CHEMBL2116	Homo sapiens	log2FC		-0.27
	19073237	CHEMBL4362155	Effect on AMPK alpha2 at T172 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	log2FC		-0.04	CHEMBL2116	Homo sapiens	log2FC		-0.04
	19090032	CHEMBL4365606	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	90.0	CHEMBL2116	Homo sapiens	Activity	%	90.0
	19144614	CHEMBL4377630	Inhibition of full length recombinant human AMPK alpha2 at 1 uM using AMARAASAAALARRR as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	20.0	CHEMBL2116	Homo sapiens	INH	%	20.0
	19146820	CHEMBL4378972	Inhibition of recombinant full length human AMPKalpha2 at 10 uM using AMARAASAAALARRR as substrate after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	5.0	CHEMBL2116	Homo sapiens	INH	%	5.0
	19147745	CHEMBL4379141	Inhibition of human full length AMPKalpha2 recombinant using AMARAASAAALAR as substrate incubated for 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL2116	Homo sapiens	IC50	uM	10.0
	19159287	CHEMBL4382391	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	23.0	CHEMBL2116	Homo sapiens	Activity	%	23.0
	19191238	CHEMBL4389587	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	56.0	CHEMBL2116	Homo sapiens	INH	%	56.0
	19191720	CHEMBL4389110	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	4.7	CHEMBL2116	Homo sapiens	INH	%	4.7
	19200009	CHEMBL4391213	Binding affinity to wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	15.0	CHEMBL2116	Homo sapiens	Activity	%	15.0
	19275929	CHEMBL4407932	Inhibition of recombinant full length human AMPKalpha2 at 1 uM using AMARAASAAALAR as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	77.0	CHEMBL2116	Homo sapiens	INH	%	77.0
Active	22388038	CHEMBL4666376	Activation of AMPK in human H1299 cells assessed as increase in AMPK phosphorylation at 10 to 20 uM by Western blot analysis	B	O=C1c2ccccc2C(=O)c2c1cc(NS(=O)(=O)c1ccc(-c3ccccc3)cc1)c(O)c2O		CHEMBL4741748		Activity			CHEMBL2116	Homo sapiens	Activity		
	22952753	CHEMBL4766690	Inhibition of recombinant full length human AMPKalpha2 assessed as residual activity at 10 uM using AMARAASAAALARRR as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	105.0	CHEMBL2116	Homo sapiens	Activity	%	105.0
	22964296	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	IC50	nM	61.7	CHEMBL2116	Homo sapiens	IC50	nM	61.7
	22964297	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCN		CHEMBL3542333	=	IC50	nM	141.0	CHEMBL2116	Homo sapiens	IC50	nM	141.0
	22964298	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCN(C)C		CHEMBL13976	=	IC50	nM	50.4	CHEMBL2116	Homo sapiens	IC50	nM	50.4
	22964299	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCNCCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL3542344	=	IC50	nM	61.4	CHEMBL2116	Homo sapiens	IC50	nM	61.4
	22964300	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NCCCN(C)C		CHEMBL4799580	=	IC50	nM	74.8	CHEMBL2116	Homo sapiens	IC50	nM	74.8
	22964301	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL4788980	=	IC50	nM	38.6	CHEMBL2116	Homo sapiens	IC50	nM	38.6
	22964302	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL275117	=	IC50	nM	88.5	CHEMBL2116	Homo sapiens	IC50	nM	88.5
	22964303	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3cc(F)ccc32)c1C		CHEMBL4779166	=	IC50	nM	49.4	CHEMBL2116	Homo sapiens	IC50	nM	49.4
	22964304	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3cc(Cl)ccc32)c1C		CHEMBL4786972	=	IC50	nM	65.1	CHEMBL2116	Homo sapiens	IC50	nM	65.1
	22964305	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3cc(Br)ccc32)c1C		CHEMBL4782796	=	IC50	nM	82.5	CHEMBL2116	Homo sapiens	IC50	nM	82.5
	22964306	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(C#N)cc32)c1C		CHEMBL4794096	=	IC50	nM	16.2	CHEMBL2116	Homo sapiens	IC50	nM	16.2
	22964307	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CNC(N)=O)cc32)c1C		CHEMBL4792246	=	IC50	nM	83.6	CHEMBL2116	Homo sapiens	IC50	nM	83.6
	22964308	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCOC)cc32)c1C		CHEMBL4781062	=	IC50	nM	96.6	CHEMBL2116	Homo sapiens	IC50	nM	96.6
	22964309	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCOC(C)=O)cc32)c1C		CHEMBL4799631	=	IC50	nM	111.0	CHEMBL2116	Homo sapiens	IC50	nM	111.0
	22964310	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCO)cc32)c1C		CHEMBL4800500	=	IC50	nM	20.5	CHEMBL2116	Homo sapiens	IC50	nM	20.5
	22964311	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCC#N)cc32)c1C		CHEMBL4788376	=	IC50	nM	32.4	CHEMBL2116	Homo sapiens	IC50	nM	32.4
	22964312	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCC(N)=O)cc32)c1C		CHEMBL4781578	=	IC50	nM	60.7	CHEMBL2116	Homo sapiens	IC50	nM	60.7
	22964313	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCN(C)C)cc32)c1C		CHEMBL4779730	=	IC50	nM	154.0	CHEMBL2116	Homo sapiens	IC50	nM	154.0
	22964314	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCNC(C)=O)cc32)c1C		CHEMBL4795330	=	IC50	nM	108.0	CHEMBL2116	Homo sapiens	IC50	nM	108.0
	22964315	CHEMBL4769105	Inhibition of recombinant human His6-tagged AMPK alpha2 using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCN=[N+]=[N-])cc32)c1C		CHEMBL4796639	=	IC50	nM	101.0	CHEMBL2116	Homo sapiens	IC50	nM	101.0
	22964316	CHEMBL4769106	Inhibition of recombinant human His6-tagged AMPK alpha2 at 10 uM using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay relative to control	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)O		CHEMBL1778707	=	Inhibition	%	85.0	CHEMBL2116	Homo sapiens	INH	%	85.0
	22964317	CHEMBL4769106	Inhibition of recombinant human His6-tagged AMPK alpha2 at 10 uM using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)N(C)c3ccc(F)cc32)c1C		CHEMBL4799798	=	Inhibition	%	17.0	CHEMBL2116	Homo sapiens	INH	%	17.0
	22964318	CHEMBL4769106	Inhibition of recombinant human His6-tagged AMPK alpha2 at 10 uM using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay relative to control	B	CCCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL4795455	=	Inhibition	%	48.0	CHEMBL2116	Homo sapiens	INH	%	48.0
	22964319	CHEMBL4769106	Inhibition of recombinant human His6-tagged AMPK alpha2 at 10 uM using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3cc(C)ccc32)c1C		CHEMBL4787722	=	Inhibition	%	88.0	CHEMBL2116	Homo sapiens	INH	%	88.0
	22964320	CHEMBL4769106	Inhibition of recombinant human His6-tagged AMPK alpha2 at 10 uM using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay relative to control	B	CCc1ccc2c(c1)NC(=O)/C2=C\c1[nH]c(C)c(C(=O)NCCN(CC)CC)c1C		CHEMBL4785831	=	Inhibition	%	90.0	CHEMBL2116	Homo sapiens	INH	%	90.0
	22964321	CHEMBL4769106	Inhibition of recombinant human His6-tagged AMPK alpha2 at 10 uM using ULight CRBtide as substrate incubated for 1 hr followed by substrate addition and measured after 1 hr by TR-FRET assay relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3cc(C(C)C)ccc32)c1C		CHEMBL4777514	=	Inhibition	%	69.0	CHEMBL2116	Homo sapiens	INH	%	69.0
	22964383	CHEMBL4769120	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Inhibition	%	46.0	CHEMBL2116	Homo sapiens	INH	%	46.0
	22964384	CHEMBL4769120	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCO)cc32)c1C		CHEMBL4800500	=	Inhibition	%	35.0	CHEMBL2116	Homo sapiens	INH	%	35.0
	22964385	CHEMBL4769120	Inhibition of wild-type human partial length AMPK alpha2 (M1 to E306 residues) expressed in bacterial expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCC(N)=O)cc32)c1C		CHEMBL4781578	=	Inhibition	%	64.0	CHEMBL2116	Homo sapiens	INH	%	64.0
	23120172	CHEMBL4804342	Inhibition of AMPKa2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	IC50	nM	1800.0	CHEMBL2116	Homo sapiens	IC50	uM	1.8
	23120173	CHEMBL4804342	Inhibition of AMPKa2 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1	Outside typical range	CHEMBL4860979	=	IC50	nM	-1600.0	CHEMBL2116	Homo sapiens	IC50	uM	-1.6
	23120174	CHEMBL4804342	Inhibition of AMPKa2 in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1	Outside typical range	CHEMBL4867931	=	IC50	nM	-8200.0	CHEMBL2116	Homo sapiens	IC50	uM	-8.2
	23120175	CHEMBL4804342	Inhibition of AMPKa2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	IC50	nM	20500.0	CHEMBL2116	Homo sapiens	IC50	uM	20.5
	23120176	CHEMBL4804342	Inhibition of AMPKa2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	IC50	nM	39000.0	CHEMBL2116	Homo sapiens	IC50	uM	39.0
	23120177	CHEMBL4804342	Inhibition of AMPKa2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	IC50	nM	52000.0	CHEMBL2116	Homo sapiens	IC50	uM	52.0
	23121217	CHEMBL4804524	Inhibition of AMPKa2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL2116	Homo sapiens	INH	%	0.0
	23121218	CHEMBL4804524	Inhibition of AMPKa2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL2116	Homo sapiens	INH	%	0.0
	23121219	CHEMBL4804524	Inhibition of AMPKa2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	0.0	CHEMBL2116	Homo sapiens	INH	%	0.0
	23121220	CHEMBL4804524	Inhibition of AMPKa2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	0.0	CHEMBL2116	Homo sapiens	INH	%	0.0
	23121221	CHEMBL4804524	Inhibition of AMPKa2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	35.0	CHEMBL2116	Homo sapiens	INH	%	35.0
	23121222	CHEMBL4804524	Inhibition of AMPKa2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	50.0	CHEMBL2116	Homo sapiens	INH	%	50.0
	23122445	CHEMBL4804796	Inhibition of human AMPK-alpha2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	42.0	CHEMBL2116	Homo sapiens	Activity	%	42.0
	23123140	CHEMBL4805384	Inhibition of human AMPK-alpha2 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	93.0	CHEMBL2116	Homo sapiens	Activity	%	93.0
	23123747	CHEMBL4805991	Inhibition of DNA-tagged human AMPK-alpha2 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	100.0	CHEMBL2116	Homo sapiens	Activity	%	100.0
	23124370	CHEMBL4806401	Inhibition of human AMPK-alpha2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	80.0	CHEMBL2116	Homo sapiens	Activity	%	80.0
	23124371	CHEMBL4806401	Inhibition of human AMPK-alpha2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	95.0	CHEMBL2116	Homo sapiens	Activity	%	95.0
Not Active	23317280	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	88.0	CHEMBL2116	Homo sapiens	% Control	%	88.0
Not Active	23317748	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23318422	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23318898	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	87.0	CHEMBL2116	Homo sapiens	% Control	%	87.0
Not Active	23319538	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23320010	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	92.6	CHEMBL2116	Homo sapiens	% Control	%	92.6
Not Active	23320688	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23321156	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23321786	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23322254	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	95.0	CHEMBL2116	Homo sapiens	% Control	%	95.0
Not Active	23322943	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23323411	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	98.0	CHEMBL2116	Homo sapiens	% Control	%	98.0
Not Active	23324265	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	95.3	CHEMBL2116	Homo sapiens	% Control	%	95.3
Not Active	23324900	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23325368	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23326015	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	82.0	CHEMBL2116	Homo sapiens	% Control	%	82.0
Not Active	23326483	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	87.0	CHEMBL2116	Homo sapiens	% Control	%	87.0
Not Active	23327183	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23327651	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23328238	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23328706	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23329247	CHEMBL4880954	AMPK2(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	109.0	CHEMBL2116	Homo sapiens	% residual kinase activity	%	109.0
Not Active	23329652	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23330120	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23330876	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23331344	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	66.0	CHEMBL2116	Homo sapiens	% Control	%	66.0
Not Active	23331931	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	82.7	CHEMBL2116	Homo sapiens	% Control	%	82.7
Not Active	23332399	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23333115	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	80.4	CHEMBL2116	Homo sapiens	% Control	%	80.4
Not Active	23333754	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	97.0	CHEMBL2116	Homo sapiens	% Control	%	97.0
Not Active	23334222	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23335201	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	89.0	CHEMBL2116	Homo sapiens	% Control	%	89.0
Not Active	23335669	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	97.0	CHEMBL2116	Homo sapiens	% Control	%	97.0
Not Active	23336296	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23336764	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	97.0	CHEMBL2116	Homo sapiens	% Control	%	97.0
Not Active	23337845	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23338313	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	86.0	CHEMBL2116	Homo sapiens	% Control	%	86.0
Not Active	23338925	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	97.0	CHEMBL2116	Homo sapiens	% Control	%	97.0
Not Active	23339393	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23340030	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23340498	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	97.0	CHEMBL2116	Homo sapiens	% Control	%	97.0
Not Active	23341155	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23341623	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23342239	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	88.0	CHEMBL2116	Homo sapiens	% Control	%	88.0
Not Active	23342707	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	74.0	CHEMBL2116	Homo sapiens	% Control	%	74.0
Not Active	23343337	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	88.0	CHEMBL2116	Homo sapiens	% Control	%	88.0
Not Active	23343805	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	91.0	CHEMBL2116	Homo sapiens	% Control	%	91.0
Not Active	23344443	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23345016	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	87.0	CHEMBL2116	Homo sapiens	% Control	%	87.0
Not Active	23345484	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	71.0	CHEMBL2116	Homo sapiens	% Control	%	71.0
Not Active	23346061	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23346530	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	94.7	CHEMBL2116	Homo sapiens	% Control	%	94.7
Not Active	23347140	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	59.6	CHEMBL2116	Homo sapiens	% Control	%	59.6
Not Active	23347621	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23348200	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23348668	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	85.0	CHEMBL2116	Homo sapiens	% Control	%	85.0
Not Active	23349255	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	96.0	CHEMBL2116	Homo sapiens	% Control	%	96.0
Not Active	23349873	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23350341	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	71.0	CHEMBL2116	Homo sapiens	% Control	%	71.0
Not Active	23350946	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23351414	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23352438	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23352906	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23353788	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23354256	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23354988	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23355456	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23356092	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23356560	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23357169	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23357816	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23358284	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	96.0	CHEMBL2116	Homo sapiens	% Control	%	96.0
Not Active	23358870	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	70.5	CHEMBL2116	Homo sapiens	% Control	%	70.5
Not Active	23359468	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	94.0	CHEMBL2116	Homo sapiens	% Control	%	94.0
Not Active	23359936	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	96.0	CHEMBL2116	Homo sapiens	% Control	%	96.0
Not Active	23360521	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	97.0	CHEMBL2116	Homo sapiens	% Control	%	97.0
Not Active	23360989	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23361562	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23362098	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23362566	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	96.0	CHEMBL2116	Homo sapiens	% Control	%	96.0
Not Active	23364208	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	93.0	CHEMBL2116	Homo sapiens	% Control	%	93.0
Not Active	23364676	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23365415	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	99.0	CHEMBL2116	Homo sapiens	% Control	%	99.0
Not Active	23365958	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	87.0	CHEMBL2116	Homo sapiens	% Control	%	87.0
Not Active	23366548	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23367016	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23367894	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	79.0	CHEMBL2116	Homo sapiens	% Control	%	79.0
Not Active	23368362	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	51.0	CHEMBL2116	Homo sapiens	% Control	%	51.0
Not Active	23368961	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23369429	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23369973	CHEMBL4884219	AMPKalpha2(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	0.0	CHEMBL2116	Homo sapiens	% residual kinase activity	%	0.0
	23369974	CHEMBL4884219	AMPKalpha2(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		IC50	nM	7.0	CHEMBL2116	Homo sapiens	IC50	nM	7.0
Active	23370397	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	0.0	CHEMBL2116	Homo sapiens	% Control	%	0.0
Not Active	23370865	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	99.0	CHEMBL2116	Homo sapiens	% Control	%	99.0
Not Active	23371674	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	79.0	CHEMBL2116	Homo sapiens	% Control	%	79.0
Not Active	23372142	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
	23372855	CHEMBL4884820	AMPKalpha2(PRA2LGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL2116	Homo sapiens	pIC50		6.0
	23373264	CHEMBL4885111	AMPKalpha2(PRA2LGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL2116	Homo sapiens	pIC50		6.0
	23373620	CHEMBL4885397	AMPKalpha2(PRA2LGY1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL2116	Homo sapiens	pIC50		6.0
Not Active	23375356	CHEMBL4886338	protein kinase, AMP-activated, alpha 2 catalytic subunit Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	2.0	CHEMBL2116	Homo sapiens	% inhibition	%	2.0
Not Active	23375569	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23376037	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	81.0	CHEMBL2116	Homo sapiens	% Control	%	81.0
Not Active	23376615	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23377084	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23377942	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	99.0	CHEMBL2116	Homo sapiens	% Control	%	99.0
Not Active	23378410	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	57.0	CHEMBL2116	Homo sapiens	% Control	%	57.0
Not Active	23379577	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23380045	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Slightly Active	23380739	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	28.0	CHEMBL2116	Homo sapiens	% Control	%	28.0
Not Active	23381387	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23381855	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23382479	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23382947	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	87.0	CHEMBL2116	Homo sapiens	% Control	%	87.0
Not Active	23384178	CHEMBL4887773	AMPKalpha2(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	-5.39	CHEMBL2116	Homo sapiens	% inhibition	%	-5.39
Not Active	23384862	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL2116	Homo sapiens	% Control	%	100.0
Not Active	23385329	CHEMBL4879586	KinomeScan assay: inhibition of AMPK-alpha2	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	78.0	CHEMBL2116	Homo sapiens	% Control	%	78.0
